var title_f32_28_33216="Collagenase: Drug information";
var content_f32_28_33216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Collagenase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12929897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12931136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/29/5588?source=see_link\">",
"       Collagenase (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/11/41138?source=see_link\">",
"       Collagenase (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16759 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33216=[""].join("\n");
var outline_f32_28_33216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/29/5588?source=related_link\">",
"      Collagenase (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/11/41138?source=related_link\">",
"      Collagenase (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_28_33217="Portable chest x-ray rib fractures";
var content_f32_28_33217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Portable chest x-ray rib fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP portable film of the chest (A, and magnified in B) reveals acute fractures of the lateral aspects of left sided ribs 2, 3, and 4 (red arrows) following trauma. No pneumothorax is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33217=[""].join("\n");
var outline_f32_28_33217=null;
var title_f32_28_33218="Plasma cell granuloma low";
var content_f32_28_33218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low magnification photomicrograph of inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung. The tumor is composed of a combination of spindle cells and mononuclear inflammatory cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33218=[""].join("\n");
var outline_f32_28_33218=null;
var title_f32_28_33219="Psoriasis plaque";
var content_f32_28_33219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous plaque with coarse scale is present on the knee of this patient with psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33219=[""].join("\n");
var outline_f32_28_33219=null;
var title_f32_28_33220="Double duct sign in pancreatic cancer";
var content_f32_28_33220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    \"Double duct\" sign in a patient with pancreatic cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography (ERCP) in a patient with adenocarcinoma in the head of the pancreas. The common bile duct is dilated proximal to a stricture (arrow). In addition, the pancreatic duct is dilated (arrowhead) due to obstruction by the tumor. The dilation of both the common bile duct and the pancreatic duct is known as the \"double duct\" sign, a finding that is highly suggestive of a malignancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33220=[""].join("\n");
var outline_f32_28_33220=null;
var title_f32_28_33221="Histology lung 2A answer";
var content_f32_28_33221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73243%7EID%2F82517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73243%7EID%2F82517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary coccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of a hematoxylin and eosin-stained section of lung tissue (x400) shows a large spherule of Coccidioides immitis, which contains many endospores. Identification of this organism may also be made by fungal culture on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coccidioides immitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swartz-Lamkin's wet mount of cocciodioides immitis from a fungal culture on Sabouraud's agar (x400). Barrel-shaped arthrospores are found in the mycelial phase of this organism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33221=[""].join("\n");
var outline_f32_28_33221=null;
var title_f32_28_33222="Aprepitant: Drug information";
var content_f32_28_33222=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aprepitant: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/22/24932?source=see_link\">",
"    see \"Aprepitant: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/46/38630?source=see_link\">",
"    see \"Aprepitant: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5498119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Substance P/Neurokinin 1 Receptor antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of chemotherapy-induced nausea/vomiting:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Highly-emetogenic chemotherapy: 125 mg 1 hour prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3 (in combination with a  5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist antiemetic on day 1 and dexamethasone on days 1-4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderately-emetogenic chemotherapy: 125 mg 1 hour prior to chemotherapy on day 1, followed by 80 mg once daily on days 2 and 3 (in combination with a 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist antiemetic and dexamethasone on day 1)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of PONV:",
"     </b>",
"     Oral: 40 mg within 3 hours prior to induction",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F136353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     ESRD undergoing dialysis: No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F136354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use with caution; no data available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emend&reg;: 40 mg, 80 mg, 125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package, oral [each package contains]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emend&reg;: Capsule: 80 mg (2s) and Capsule: 125 mg (1s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chemotherapy-induced nausea/vomiting: Administer with or without food. First dose should be given 1 hour prior to antineoplastic therapy; subsequent doses should be given in the morning.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PONV: Administer within 3 hours prior to induction; follow healthcare providers instructions about food/drink restrictions prior to surgery.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of acute and delayed nausea and vomiting associated with moderately- and highly-emetogenic chemotherapy (in combination with other antiemetics); prevention of postoperative nausea and vomiting (PONV)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5656106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aprepitant may be confused with fosaprepitant",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Emend&reg; (aprepitant) oral capsule formulation may be confused with Emend&reg; for injection (fosaprepitant)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions reported as part of a combination chemotherapy regimen or with general anesthesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (&le;18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6% to 13%), constipation (9% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&le;18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hiccups (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (&le;6%), bradycardia (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (&le;10%), dyspepsia (&le;6%), abdominal pain (&le;5%), epigastric discomfort (4%), gastritis (4%), stomatitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (&le;6%), AST increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Proteinuria (7%), BUN increased (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;0.5% (Limited to important or life-threatening): Acid reflux, acne, albumin decreased, alkaline phosphatase increased, anaphylactic reaction, anemia, angioedema, anxiety, appetite decreased, arthralgia, back pain, bilirubin increased, candidiasis, confusion, conjunctivitis, cough, deglutition disorder, depression, diabetes mellitus, diaphoresis, disorientation, duodenal ulcer (perforating), DVT, dysarthria, dysphagia, dyspnea, dysuria, edema, enterocolitis, eructation, erythrocyturia, febrile neutropenia, flatulence, flushing, glucosuria, herpes simplex, hyperglycemia, hypersensitivity reaction, hypertension, hypoesthesia, hypokalemia, hyponatremia, hypothermia, hypovolemia, hypoxia, leukocytes increased, leukocyturia, malaise, MI, miosis, muscular weakness, musculoskeletal pain, myalgia, nasal secretion, neutropenic sepsis, obstipation, pain, palpitation, pelvic pain, peripheral neuropathy, pharyngitis, pharyngolaryngeal pain, pneumonia, pneumonitis, pruritus, pulmonary embolism, rash, renal insufficiency, respiratory infection, respiratory insufficiency, rigors, salivation increased, sensory disturbance, sensory neuropathy, septic shock, Stevens-Johnson syndrome, syncope, tachycardia, taste disturbance, thrombocytopenia, toxic epidermal necrolysis, tremor, urinary tract infection, urticaria, visual acuity decreased, vocal disturbance, weight loss, wheezing, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aprepitant or any component of the formulation; concurrent use with cisapride or pimozide",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment (Child-Pugh class C); has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nausea/vomiting: Appropriate use: Not studied for treatment of existing nausea and vomiting. Chronic continuous administration is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug  interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F136361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP3A4 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (strong), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Aprepitant may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Aprepitant may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Aprepitant may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Aprepitant may decrease the serum concentration of Contraceptives (Progestins).  Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Aprepitant may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: Aprepitant may increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: Aprepitant may decrease the serum concentration of PARoxetine. PARoxetine may decrease the serum concentration of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Aprepitant may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TOLBUTamide: Aprepitant may decrease the serum concentration of TOLBUTamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Aprepitant may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F136346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Aprepitant serum concentration may be increased when taken with grapefruit juice; avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease aprepitant levels).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Use during pregnancy only if clearly needed.  Efficacy of hormonal contraceptive may be reduced; alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least 1 month following the last fosaprepitant/aprepitant dose.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F136357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16132204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reactions in the nursing infant, the decision to discontinue aprepitant or to discontinue breast-feeding should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F136336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Emend Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $65.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (2): $251.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 &amp; 125 mg (3): $445.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (6): $1179.58",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5498259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Emend (AR, AT, AU, BE, BG, BR, CH, CN, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HN, IE, IL, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PT, RU, SE, SG, SK, SV, TH, TR, TW, VE);",
"     </li>",
"     <li>",
"      Emend Tri-Pack (HK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevents acute and delayed vomiting by inhibiting the substance P/neurokinin 1 (NK",
"     <sub>",
"      1",
"     </sub>",
"     ) receptor; augments the antiemetic activity of 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists and corticosteroids to inhibit acute and delayed phases of chemotherapy-induced emesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~70 L; crosses the blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4 (major); CYP1A2 and CYP2C19 (minor); forms 7 metabolites (weakly active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~60% to 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~9-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~3-4 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Basch E, Prestrud AA, Hesketh PJ, et al, \"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(31):4189-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/28/33222/abstract-text/21947834/pubmed\" id=\"21947834\" target=\"_blank\">",
"        21947834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kris MG, Hesketh PJ, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2932-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/28/33222/abstract-text/16717289/pubmed\" id=\"16717289\" target=\"_blank\">",
"        16717289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Multinational Association of Supportive Care in Cancer, MASCC/ESMO &ldquo;Antiemetic Guideline 2011,&rdquo; Updated April 2011. Available at  file://www.mascc.org/assets/documents/MASCC_Guidelines_English_2011.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Antiemesis,&rdquo; Version 1.2013. Available at  file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9305 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33222=[""].join("\n");
var outline_f32_28_33222=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5498119\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136367\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136351\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136352\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136353\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136354\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136328\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136315\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136331\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136330\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5656106\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136365\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136334\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136319\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136361\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136346\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136325\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136335\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136357\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16132204\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136336\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422188\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5498259\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136318\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136333\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9305\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9305|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/22/24932?source=related_link\">",
"      Aprepitant: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/46/38630?source=related_link\">",
"      Aprepitant: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_28_33223="Arrhythmia management for the primary care clinician";
var content_f32_28_33223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Arrhythmia management for the primary care clinician",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33223/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33223/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33223/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33223/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33223/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33223/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/28/33223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians in many disciplines commonly face the problem of evaluating and treating patients with cardiac arrhythmias (",
"    <a class=\"graphic graphic_table graphicRef72601 \" href=\"mobipreview.htm?33/32/34315\">",
"     table 1",
"    </a>",
"    ). Carefully performed randomized trials, technological advances, and better understanding of arrhythmia mechanisms have resulted in improved approaches to rhythm disturbances. Basic evaluation and management principles are key to the initial approach to the patient with an arrhythmia.",
"   </p>",
"   <p>",
"    There are three reasons to evaluate and treat arrhythmias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eliminate symptoms.",
"     </li>",
"     <li>",
"      Prevent imminent death and hemodynamic collapse due to a life-threatening arrhythmia.",
"     </li>",
"     <li>",
"      Reduce possible risks other than the direct effects of the arrhythmia (eg, reduce stroke in patients with atrial fibrillation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will provide an overview of early diagnosis and management of rhythm disturbances in patients who present to by primary care physicians. The reader will be referred to detailed discussions of the individual arrhythmias. The role of the primary care physician in the evaluation of palpitations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An arrhythmia is any rhythm that is not normal sinus rhythm with normal atrioventricular (AV) conduction. Normal sinus rhythm originates from the sinus node in the upper portion of the right atrium. During sinus rhythm, the heart rate is in the normal range, the P waves are normal on the ECG, and the rate is stable.",
"   </p>",
"   <p>",
"    The normal sinus rate has been considered to be between 60 and 100",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    However, the range (defined by 2 standard deviations from the mean) is between 43 and 93",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    in men and 52 and 94",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    for women. Sinus bradycardia or tachycardia may be physiologic (ie, normal) or nonphysiologic (ie, abnormal); each is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=see_link\">",
"     \"Sinus bradycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=see_link\">",
"     \"Sinus tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sinus arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not uncommonly the activation rate of the sinus node varies, leading to a variable P-P interval on the ECG. If the variation of the P-P interval is 0.12 sec (120 msec) or more in the presence of normal P waves, this is known as sinus arrhythmia. Sinus arrhythmia is usually physiologic and is related to respiratory cycles. It does not require treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2086?source=see_link\">",
"     \"Normal sinus rhythm and sinus arrhythmia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMMON ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common arrhythmias encountered in an office-based setting include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial premature beats (APBs)",
"     </li>",
"     <li>",
"      Ventricular premature beats (VPBs) (",
"      <a class=\"graphic graphic_waveform graphicRef74977 \" href=\"mobipreview.htm?13/48/14083\">",
"       waveform 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bradycardias (",
"      <a class=\"graphic graphic_waveform graphicRef78649 \" href=\"mobipreview.htm?24/22/24931\">",
"       waveform 2",
"      </a>",
"      ), including sinus bradycardia (",
"      <a class=\"graphic graphic_waveform graphicRef78649 \" href=\"mobipreview.htm?24/22/24931\">",
"       waveform 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65521 \" href=\"mobipreview.htm?11/49/12061\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ventricular Tachycardia (",
"      <a class=\"graphic graphic_waveform graphicRef69201 graphicRef54513 \" href=\"mobipreview.htm?25/24/25994\">",
"       waveform 3A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrial fibrillation (AF) and atrial flutter (",
"      <a class=\"graphic graphic_waveform graphicRef64217 graphicRef75931 \" href=\"mobipreview.htm?15/52/16201\">",
"       waveform 4A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Supraventricular tachyarrhythmias (SVTs) (",
"      <a class=\"graphic graphic_waveform graphicRef56931 \" href=\"mobipreview.htm?4/28/4547\">",
"       waveform 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef54290 \" href=\"mobipreview.htm?32/3/32830\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrioventricular (AV) block (",
"      <a class=\"graphic graphic_waveform graphicRef51492 \" href=\"mobipreview.htm?16/4/16452\">",
"       waveform 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nonsustained ventricular tachycardia (NSVT) (",
"      <a class=\"graphic graphic_waveform graphicRef73299 \" href=\"mobipreview.htm?1/3/1080\">",
"       waveform 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Follow-up of already treated VT or ventricular fibrillation (VF)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of these arrhythmias may be difficult, even for an experienced specialist in rhythm disturbances. As an example, the etiology of wide or narrow QRS tachycardias may be difficult based upon the electrocardiogram (ECG); an electrophysiology study is occasionally indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some rhythm disturbances, such as symptomatic bradycardia (with syncope or near syncope) or sustained ventricular tachycardia, require urgent attention. Others, such as ectopic atrial and ventricular beats, may cause concern but do not need immediate management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients typically seek medical care for symptoms associated with an arrhythmia. They may also request or require evaluation if there are other abnormalities that place a patient at risk for an arrhythmia, such as a delta wave or a long QT interval on an electrocardiogram, or hypertrophic cardiomyopathy seen by an echocardiogram. Occasionally, an asymptomatic patient who has an irregular pulse on examination, or who has an ECG, ambulatory monitor, or exercise test for another reason is found to have an arrhythmia or evidence that may indicate an arrhythmia may be present.",
"   </p>",
"   <p>",
"    When the primary care physician first encounters a patient with an arrhythmia, the following questions should be addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the arrhythmia causing symptoms or could it?",
"     </li>",
"     <li>",
"      Does the arrhythmia pose a risk to the patient?",
"     </li>",
"     <li>",
"      Which arrhythmia is present?",
"     </li>",
"     <li>",
"      Does the arrhythmia require emergent cardioversion?",
"     </li>",
"     <li>",
"      Does the patient require urgent hospitalization?",
"     </li>",
"     <li>",
"      Is specialist consultation required, and if so, how urgently?",
"     </li>",
"     <li>",
"      Should anticoagulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other medical therapy be started?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial evaluation of the patient with an arrhythmia consists of a complete history (aimed toward symptoms and timing of the arrhythmia and potential underlying diseases), physical examination and 12-lead ECG, if possible, during the arrhythmia and without it. The ECG alone during the arrhythmia may determine the type of arrhythmia and whether a particular symptom is due to the arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of symptoms may determine whether any action needs to be taken.",
"   </p>",
"   <p>",
"    Symptoms caused by cardiac arrhythmias can mimic those due to other medical disorders and include palpitations, dizziness, lightheadedness, syncope, chest discomfort, neck discomfort, dyspnea, weakness, and anxiety. Secondary consequences of arrhythmias, often due to underlying heart disease, are an additional source of symptoms (eg, congestive heart failure, ischemia, and thromboemboli.) Arrhythmias such as ventricular fibrillation and asystole can cause cardiac arrest.",
"   </p>",
"   <p>",
"    Cardiac arrhythmias can have unusual symptomatic presentations such as tinnitus, visual changes, increased urinary frequency, abdominal discomfort, and peripheral edema. Arrhythmias may cause a change in sympathetic and vagal tone, hormonal changes, elevation of venous pressure, and reduced cardiac output, all of which can lead to an even longer list of other symptoms.",
"   </p>",
"   <p>",
"    Symptom type and severity are related to the etiology and rate of the arrhythmia, to the nature and severity of underlying heart disease, and to the patient. The symptom severity often dictates the urgency for therapy or even the need to evaluate and treat. The presence of structural heart disease is a key issue that determines the urgency of intervention, evaluation, therapy, and the prognostic importance of the arrhythmia.",
"   </p>",
"   <p>",
"    Arrhythmias commonly cause palpitations. The approach to the patient who presents with palpitations is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the history and physical exam may strongly suggest the diagnosis, such as in a patient with lightheadedness and a rapid and irregularly irregular pulse (atrial fibrillation), the diagnosis is best made with an electrocardiogram or a monitor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34438?source=see_link\">",
"     \"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=see_link\">",
"     \"ECG tutorial: Atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37687?source=see_link\">",
"     \"ECG tutorial: Basic principles of ECG analysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22038?source=see_link\">",
"     \"ECG tutorial: Intraventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29077?source=see_link\">",
"     \"ECG tutorial: Rhythms and arrhythmias of the sinus node\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1942?source=see_link\">",
"     \"ECG tutorial: Ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with a suspected arrhythmia have a paroxysmal pattern, so that the ECG recorded in the absence of symptoms is either normal or does not suggest a specific arrhythmia. Four types of outpatient monitoring systems are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traditional Holter-continuous recording of 24 or 48 hours.",
"     </li>",
"     <li>",
"      Event recorder-patient activated recorder, either looping or nonlooping. Some newer models have automatic arrhythmia detection software to store asymptomatic episodes. Data is transmitted over the phone to a monitoring station.",
"     </li>",
"     <li>",
"      Mobile continuous outpatient cardiac telemetry-continuous recording and analysis, with symptomatic or algorithm defined episodes transmitted automatically via cellular technology to monitoring station.",
"     </li>",
"     <li>",
"      Implantable loop recorder-patient and algorithm defined episodes stored in device, until interrogated either in office or remotely via home equipment and internet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 1999 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on ambulatory electrocardiography concluded that there were two main indications for ambulatory monitoring in the assessment of arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33223/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the assessment of unexplained syncope, near syncope, or episodic dizziness",
"     </li>",
"     <li>",
"      For the assessment of unexplained recurrent palpitations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An event recorder or transtelephonic monitor can help make the diagnosis in a patient with less frequent palpitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33223/abstract/2\">",
"     2",
"    </a>",
"    ]. Transtelephonic ECG devices exist in several forms of recorders and transmitters capable of direct transmission of an electrocardiogram as an audio signal by telephone. These ECG signals are most commonly received at a base station equipped with a demodulator and an ECG strip chart recorder. Although such devices usually provide limited, noncontinuous sample ECG data, the device may be used in either a noncontinuous or continuous format.",
"   </p>",
"   <p>",
"    Noncontinuously applied transtelephonic devices with memory are small (beeper size), lightweight instruments that are generally inexpensive. These devices are carried by the patient; they can be applied with temporary contact to the precordial area, or are attached by electrodes and worn continuously. The memory feature allows recording of data without the need for immediate access to telephone transmission.",
"   </p>",
"   <p>",
"    The latest innovation of transtelephonic monitoring uses a readily available wrist recorder whose circuitry is completed by contact of the index finger and thumb, or hand contact to the opposite wrist. This action results in the loop storage of a four to five minute ECG sample of lead I, and permits direct printout or transtelephonic transmission. The stored data may be transmitted by telephone directly to a facsimile machine. An implantable monitor (Reveal, Medtronic, Minneapolis, USA) is available in Europe and will be available soon in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If episodes are associated with exercise or physical or mental stress or when an arrhythmia cannot be documented with ambulatory or transtelephonic monitoring, a treadmill or bicycle ergometer may be helpful to establish the presence and mechanism of the arrhythmia.",
"   </p>",
"   <p>",
"    In some instances, such as in selected patients with unexplained syncope, an implantable loop recorder may be indicated to detect the arrhythmia that may be responsible for patient symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=see_link&amp;anchor=H8#H8\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\", section on 'Implantable loop recorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patients presenting with an arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic arrhythmias rarely require urgent treatment. In such patients, a physician may choose to refer the patient on an elective basis to a cardiologist or cardiac electrophysiologist.",
"   </p>",
"   <p>",
"    For patients who are symptomatic in the office, the management strategy will depend both on the characteristics of the symptoms and the type of arrhythmia present. In the following clinical scenarios, we recommend urgent transfer to a facility with emergency care capabilities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Syncope or near syncope in patients with high degree AV block or bradycardia",
"     </li>",
"     <li>",
"      Wide complex sustained rhythms (other than sinus with bundle branch block) including ventricular tachycardia",
"     </li>",
"     <li>",
"      Patients in whom the diagnosis is uncertain after examination and ECG, but for whom there is a concern about a life threatening arrhythmia",
"     </li>",
"     <li>",
"      Patients with a history of coronary artery disease, cardiomyopathy, or heart failure and syncope, near syncope,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      documented ventricular arrhythmia",
"     </li>",
"     <li>",
"      Sustained supraventricular tachycardia (SVT)",
"     </li>",
"     <li>",
"      Atrial fibrillation or flutter with rapid or slow rates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergent cardioversion is not indicated for any conscious patient, including those with ventricular tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Referral to a specialist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias such as isolated APBs or VPBs, or atrial fibrillation are common in the general population and many primary care physicians are comfortable and capable of managing patients with these. We suggest elective referral to a cardiologist for the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any patient with an arrhythmia when the primary care physician is uncomfortable with either diagnosis or management",
"     </li>",
"     <li>",
"      Candidates for permanent pacing",
"     </li>",
"     <li>",
"      Those with an uncertain diagnosis, prognosis, or management strategy",
"     </li>",
"     <li>",
"      Those who might benefit from implantation of an implantable cardioverter defibrillator or biventricular pacemaker",
"     </li>",
"     <li>",
"      Those who might benefit from a catheter ablation procedure",
"     </li>",
"     <li>",
"      Those who might benefit from antiarrhythmic drug therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     THERAPEUTIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy for any arrhythmia is to improve symptoms and to prevent a potentially serious outcome, primarily a life-threatening arrhythmia and sudden death. Stroke prevention in patients with atrial fibrillation and atrial flutter is also an important treatment objective. The decision to initiate a long-term treatment strategy, whether it be with device or drug therapy, depends upon the severity and frequency of arrhythmia-related symptoms compared to the risks associated with the therapy itself.",
"   </p>",
"   <p>",
"    The need for long-term therapy must be carefully individualized to each patient since the severity and importance of symptoms are highly variable. The symptoms associated with any arrhythmia can have an impact on lifestyle, occupation, driving, and other important daily activities.",
"   </p>",
"   <p>",
"    In most cases, initiation of antiarrhythmic drug therapy will be by a cardiologist or cardiac electrophysiologist. Pacemakers, ICDs and biventricular devices are generally implanted by electrophysiologists or other physicians with special training and certification in their placement. The ability to interrogate the devices long term is also necessary. The long-term follow-up of patients with implanted devices also requires special training and expertise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the involvement of a specialist (cardiologist or electrophysiologist) when initiation of an antiarrhythmic drug is considered. All antiarrhythmic drugs have the potential to increase ectopy or induce or aggravate monomorphic VT, torsades de pointes, VF, conduction disturbances, or bradycardia. This phenomenon is known as proarrhythmia (",
"    <a class=\"graphic graphic_table graphicRef66133 \" href=\"mobipreview.htm?19/15/19708\">",
"     table 3",
"    </a>",
"    ). The potential for major adverse outcomes, including death, requires the expertise of a specialist who understands the use and risks of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of proarrhythmia is higher for class I drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"     table 4",
"    </a>",
"    ) in patients with structural heart disease, especially coronary heart disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular dysfunction, than in patients with structurally normal heart disease. Class II drugs (beta blockers, except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , which also has class III properties at higher dosing), have no tachyarrhythmic or proarrhythmic effects but can cause bradycardia. Class III drugs prolong repolarization and pose the specific risk of torsades des pointes ventricular tachycardia.",
"   </p>",
"   <p>",
"    Although the exact incidence of proarrhythmia is not certain, it appears to be relatively low when antiarrhythmic drugs are used carefully and properly. The risk varies according to the type of arrhythmia treated, the presence of structural heart disease, the QT interval, preexisting conduction disturbances, sinus node dysfunction, patient age, the presence of heart failure, and left and right ventricular function. The proarrhythmic risk is highest in patients with depressed left ventricular function (eg, EF &lt;0.30), the group at highest risk for an arrhythmic event and sudden death; the risk is lowest in those with no organic heart disease.",
"   </p>",
"   <p>",
"    Proarrhythmia can be predictable and is most often idiosyncratic. However, it may be dose-related for specific drugs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , class IC drugs, and the metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , N-acetyl procainamide.",
"   </p>",
"   <p>",
"    Torsades de pointes is the most recognized form of drug proarrhythmia. It is characterized by a VT with a twisting of the peaks of the QRS complexes across an imaginary isoelectric line (",
"    <a class=\"graphic graphic_waveform graphicRef53891 graphicRef73827 graphicRef60231 \" href=\"mobipreview.htm?41/12/42185\">",
"     waveform 8A-C",
"    </a>",
"    ). The QT interval is prolonged, bradycardia is often present, and the arrhythmia is induced after a short-long cycle. Torsades de pointes was originally recognized as a complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    use, being the mechanism for \"quinidine syncope\". Many nonantiarrhythmic drugs including some antibiotics, antipsychotics, and other classes of drugs, can increase the risk of torsades de pointes via prolongation of the QT interval (",
"    <a class=\"graphic graphic_table graphicRef72631 \" href=\"mobipreview.htm?16/27/16828\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Initiation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with some (but not all) antiarrhythmic drugs is best initiated in the hospital, primarily to monitor for early proarrhythmia. The decision to hospitalize depends upon several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence and severity of structural heart disease.",
"     </li>",
"     <li>",
"      The indication for treatment (eg, etiology of the arrhythmia and type and severity of associated symptoms). Treatment for ventricular tachycardia is usually started in the hospital.",
"     </li>",
"     <li>",
"      The drug used. For example, the labeling information for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      specify inpatient initiation, while",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      can generally be initiated outside the hospital in appropriate patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following the initiation of an antiarrhythmic drug, patients should have periodic monitoring with an ECG and laboratory tests. The frequency of such tests is higher at the time of initiation and dose adjustment. Careful monitoring of electrolytes may help reduce the risk of proarrhythmia. Assessment of renal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatic function is also important depending on the agent(s) being used. These drugs may interact with other drugs, which also require monitoring (for example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    tends to increase the International Normalized Ratio (INR) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    level)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      should have assessment of hepatic, thyroid, and pulmonary function on a regular basis, or with any symptoms that suggest possible organ toxicity. Patients taking amiodarone should also be cautioned regarding skin photosensitivity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SPECIFIC ARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atrial fibrillation and flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion has emphasized the symptoms (eg, palpitations, syncope) and life-threatening potential of an arrhythmia itself. AF and flutter are associated with additional issues, each of which must be addressed.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reversion to sinus rhythm",
"     </li>",
"     <li>",
"      Maintenance of sinus rhythm",
"     </li>",
"     <li>",
"      Slowing the ventricular rate in chronic or paroxysmal atrial fibrillation",
"     </li>",
"     <li>",
"      Prevention of systemic embolization and stroke, both at the time of reversion and in patients chronically",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Atrial premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;An atrial premature beat (APB) is the early activation of the atria arising from a site other than the sinus node. APBs are observed on the surface electrocardiogram as a P wave that occurs relatively early in the cardiac cycle (ie, prematurely before the next sinus P wave should occur) and has a different morphology from the sinus P wave. Often the PR interval is different from that during sinus rhythm; it may be longer or shorter, depending upon the site of origin of the APB. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34438?source=see_link\">",
"     \"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APBs may be asymptomatic or cause symptoms such as a sensation of \"skipping\" or palpitations. APBs are often single and isolated, but may be frequent and may occur in a bigeminal or other repeated pattern. A",
"    <span class=\"nowrap\">",
"     trigger/stimulant",
"    </span>",
"    is often identified and its removal may eliminate or significantly reduce symptoms. Antiarrhythmic drug therapy, aside from beta blockers, is rarely recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=see_link\">",
"     \"Supraventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APB's may be blocked in the A-V conducting system. This is not necessarily pathologic, and it needs to be differentiated from atrioventricular block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ventricular premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs) are common in the general population and often cause patients to seek medical attention. This includes patients without structural heart disease and those with any form of cardiac disease, independent of severity. The evaluation and management of VPBs is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=see_link\">",
"     \"Prevalence and evaluation of ventricular premature beats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16217?source=see_link\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ARRHYTHMIA IN ATHLETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias are not infrequently documented in athletes and can be a source of morbidity and mortality, particularly ventricular tachyarrhythmia and sudden cardiac arrest. They can be a reason to consider restriction from athletics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and management of arrhythmia in athletes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ROLE OF THE PCP IN LONG-TERM CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of the PCP in the long-term care of patients with arrhythmias depends upon the particular arrhythmia diagnosis and treatment. All patients should be queried at each routine visit about changes in symptoms relevant to the arrhythmia and its treatment.",
"   </p>",
"   <p>",
"    Patients with pacemakers, implantable cardioverter defibrillators, or cardiac resynchronization therapy implantation are best followed periodically and evaluated by physicians knowledgeable in device programming, device characteristics, and their possible malfunction.",
"   </p>",
"   <p>",
"    Patients prescribed antiarrhythmic drug therapy are generally followed by a cardiologist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac electrophysiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/23/39281?source=see_link\">",
"       \"Patient information: Ventricular premature beats (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An arrhythmia is any rhythm that is not normal sinus rhythm with normal atrioventricular (AV) conduction. During sinus rhythm, the heart rate is in the normal range, the P waves are normal on the ECG, the AV conduction is normal, and the rate is stable. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When the primary care clinician first encounters a patient with an arrhythmia, the following questions should be addressed (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Approach to the patient'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the arrhythmia causing symptoms or could it?",
"     </li>",
"     <li>",
"      Does the arrhythmia pose a risk to the patient? Does the arrhythmia require emergent cardioversion?",
"     </li>",
"     <li>",
"      Which arrhythmia is present?",
"     </li>",
"     <li>",
"      Does the patient require urgent hospitalization?",
"     </li>",
"     <li>",
"      Is specialist consultation required, and if so, how urgently?",
"     </li>",
"     <li>",
"      Should anticoagulation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other medical therapy be started?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who are symptomatic in the office, the management strategy will depend both on the characteristics of the symptoms and the type of arrhythmia present. In the following clinical scenarios, we recommend urgent transfer to a facility with emergency care capabilities (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Patients presenting with an arrhythmia'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Syncope or near syncope in patients with high degree AV block or bradycardia",
"     </li>",
"     <li>",
"      Wide complex rhythms (other than sinus with bundle branch block) including ventricular tachycardia",
"     </li>",
"     <li>",
"      Patients in whom the diagnosis is uncertain after examination and ECG, but for whom there is a concern about a life threatening arrhythmia",
"     </li>",
"     <li>",
"      Patients with a history of coronary artery disease, cardiomyopathy, or heart failure and syncope, near syncope,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      documented ventricular arrhythmia",
"     </li>",
"     <li>",
"      Sustained supraventricular tachycardia (SVT)",
"     </li>",
"     <li>",
"      Atrial fibrillation or flutter with rapid or slow rates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All antiarrhythmic drugs have the potential to increase ectopy or induce or aggravate monomorphic VT, torsades de pointes, VF, conduction disturbances, or bradycardia; this known as proarrhythmia (",
"    <a class=\"graphic graphic_table graphicRef66133 \" href=\"mobipreview.htm?19/15/19708\">",
"     table 3",
"    </a>",
"    ). We suggest the involvement of a specialist (cardiologist or electrophysiologist) when initiation of an antiarrhythmic drug is considered. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Initiation of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The role of the PCP in the long-term care of patients with arrhythmias depends upon the particular arrhythmia diagnosis and treatment. All patients should be queried at each routine visit about changes in symptoms relevant to the arrhythmia and its treatment.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33223/abstract/1\">",
"      Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the guidelines for ambulatory electrocardiography). Circulation 1999; 100:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33223/abstract/2\">",
"      Zimetbaum PJ, Josephson ME. The evolving role of ambulatory arrhythmia monitoring in general clinical practice. Ann Intern Med 1999; 130:848.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 961 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33223=[""].join("\n");
var outline_f32_28_33223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sinus arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMMON ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patients presenting with an arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Referral to a specialist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      THERAPEUTIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SPECIFIC ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atrial fibrillation and flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Atrial premature beats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ARRHYTHMIA IN ATHLETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ROLE OF THE PCP IN LONG-TERM CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/961\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/961|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/3/32830\" title=\"figure 1\">",
"      Typical atrioventricular nodal reentrant tahcycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/961|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/32/34315\" title=\"table 1\">",
"      Classification arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/49/12061\" title=\"table 2\">",
"      Causes of bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/15/19708\" title=\"table 3\">",
"      Types of proarrhythmia of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/52/2892\" title=\"table 4\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/27/16828\" title=\"table 5\">",
"      Causes torsade de pointes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/961|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?13/48/14083\" title=\"waveform 1\">",
"      ECG polymorphic VPBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?24/22/24931\" title=\"waveform 2\">",
"      ECG sinus node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?25/52/26433\" title=\"waveform 3A\">",
"      ECG sustained monomorphic VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/34/32297\" title=\"waveform 3B\">",
"      Holter of monomorphic VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/12/31940\" title=\"waveform 4A\">",
"      12 lead ECG atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?32/7/32884\" title=\"waveform 4B\">",
"      12 lead ECG atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?4/28/4547\" title=\"waveform 5\">",
"      ECG atrial tachycardia with AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?16/4/16452\" title=\"waveform 6\">",
"      ECG Mobitz II heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?1/3/1080\" title=\"waveform 7\">",
"      ECG nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/23/43380\" title=\"waveform 8A\">",
"      ECG Torsades de pointes tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/7/43134\" title=\"waveform 8B\">",
"      ECG torsades de pointes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?35/15/36083\" title=\"waveform 8C\">",
"      ECG torsades de pointes and ventricular flutter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34438?source=related_link\">",
"      ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37687?source=related_link\">",
"      ECG tutorial: Basic principles of ECG analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22038?source=related_link\">",
"      ECG tutorial: Intraventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29077?source=related_link\">",
"      ECG tutorial: Rhythms and arrhythmias of the sinus node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1942?source=related_link\">",
"      ECG tutorial: Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/2/2086?source=related_link\">",
"      Normal sinus rhythm and sinus arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/23/39281?source=related_link\">",
"      Patient information: Ventricular premature beats (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=related_link\">",
"      Prevalence and evaluation of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=related_link\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=related_link\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=related_link\">",
"      Supraventricular premature beats",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_28_33224="Epidemiology, clinical manifestations, and diagnosis of giardiasis";
var content_f32_28_33224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33224/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33224/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33224/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33224/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33224/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33224/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/28/33224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giardia lamblia (also known as G. duodenalis or G. intestinalis) is a protozoan parasite capable of causing epidemic or sporadic diarrheal illness. It is an important cause of water-borne and food-borne disease, day care center outbreaks, and illness in international travelers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The life cycle, epidemiology, clinical manifestations, and diagnosis of giardiasis will be reviewed here. The treatment and prevention of giardiasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6424?source=see_link\">",
"     \"Treatment and prevention of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIFE CYCLE AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;G. lamblia has two morphological forms: cysts and trophozoites. Cysts are the infectious form of the parasite; these can survive in moist environments for prolonged periods. Ingestion of 10 to 25 cysts can lead to giardiasis; hypochlorhydria predisposes to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/4\">",
"     4",
"    </a>",
"    ]. Following cyst ingestion, excystation occurs in the proximal small bowel with release of trophozoites.",
"   </p>",
"   <p>",
"    Trophozoites are pear-shaped, binucleate, multi-flagellated parasite forms capable of division by binary fission. An adhesive disk on the ventral surface of the trophozoite facilitates attachment to the mucosal surface of the duodenum and jejunum, although the trophozoite does not invade the mucosal epithelium. Trophozoites that do not adhere to the small bowel move forward to the large intestine where they revert to the infectious cyst form; conjugated bile salts appear to foster encystation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/5\">",
"     5",
"    </a>",
"    ]. Cysts are passed back into the environment in excreted feces; in the setting of diarrhea, trophozoites can also be found in the stool.",
"   </p>",
"   <p>",
"    Since Giardia is not an invasive organism, the pathogenesis of diarrhea and malabsorption that can occur in giardiasis is not fully understood; diarrhea may be a result of both intestinal malabsorption and hypersecretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/6\">",
"     6",
"    </a>",
"    ]. The small intestine is the site of the major structural and functional abnormalities associated with giardiasis. Light microscopy may demonstrate no abnormalities, mild or moderate partial villous atrophy, or subtotal villous atrophy in severe cases. An increase in crypt depth may be seen, and microvilli shortening or disruption may occur. Deficiencies in epithelial brush border enzymes, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    , may develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic exposure to the G. lamblia may induce partial immunity; in endemic areas, children under 10 years old have higher rates of giardiasis than older individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, travelers to endemic areas have higher rates of symptomatic disease than long-term residents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Humoral immunity appears to be important for host defense against giardiasis. In particular, secretory IgA antibodies are an important humoral response to infection, since trophozoites are localized to the intestinal lumen. Patients with cystic fibrosis or immunoglobulin deficiencies (such as common variable immunodeficiency or X-linked agammaglobulinemia) tend to have more severe disease, perhaps because of deficiencies in secretory IgA. However, in the absence of other cellular immune deficiencies it is unclear whether selective IgA deficiency also leads to more severe or chronic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with HIV infection have impaired immune response to the parasite but do not seem to develop more severe disease; giardiasis is not a major cause of enteritis in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/10\">",
"     10",
"    </a>",
"    ]. Asymptomatic infections occur in the presence of HIV, although with progressive immunosuppression, the risk of symptomatic infection increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;G. lamblia infection occurs worldwide. High risk groups include infants, young children, international adoptees, travelers, immunocompromised individuals, and patients with hypochlorhydria or cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/12\">",
"     12",
"    </a>",
"    ]. Giardiasis is especially common in areas with poor sanitary conditions and insufficient water treatment facilities. In the developing world, the prevalence of giardiasis has been reported to be as high as 20 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/7,13,14\">",
"     7,13,14",
"    </a>",
"    ]. Giardia also infects mammalian animals including beavers, dogs, cattle, and sheep. Different genotypes of Giardia are almost always found in dogs and humans; therefore zoonotic transmission between dogs and humans is very uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to a surveillance report by the Centers for Disease Control (CDC), approximately 20,000 cases occur annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/16\">",
"     16",
"    </a>",
"    ]. One report in Ontario, Canada noted an adjusted incidence rate of 25.8 cases per 100,000 population between 1990 and 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/17\">",
"     17",
"    </a>",
"    ]. Almost 40 percent of cases occurred in travelers; other important sources of infection included unfiltered water and person-to-person transmission.",
"   </p>",
"   <p>",
"    The highest rates of infection occur among children younger than five years. In a study including 147 pediatric patients with acute nondysenteric diarrhea, giardiasis was the cause in 15 percent of cases, second only to rotavirus for evaluated cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/18\">",
"     18",
"    </a>",
"    ]. A German study noted a prevalence of giardiasis of 11.5 cases per 100,000 population among 1 to 5 year olds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/19\">",
"     19",
"    </a>",
"    ]. Screening for giardiasis among internationally adopted children is warranted and such children often have more than one parasitic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Routes of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giardia cysts may be transmitted via water, food, or fecal-oral transmission between infected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Water is a major source of giardiasis transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/1,22,23\">",
"     1,22,23",
"    </a>",
"    ]. Giardia cysts survive readily in mountain streams as they are hardy in cold water. Water dwelling mammals such as beavers can become infected and may serve as ongoing sources of water contamination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/24\">",
"     24",
"    </a>",
"    ]. For these reasons, giardiasis is an important cause of diarrheal illness among hikers in wilderness areas who drink water that has not been adequately filtered, treated, or boiled.",
"   </p>",
"   <p>",
"    Giardia cysts are resistant to chlorination. Deep well water is usually safe because filtration of water through soil removes Giardia cysts. Coliform counts are not a reliable measure of giardial contamination.",
"   </p>",
"   <p>",
"    Transmission of giardiasis can also occur with ingestion of raw or undercooked food contaminated with cysts, or food that is contaminated following cooking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Giardiasis is one of the more frequently identified infectious cause of traveler's diarrhea lasting more than two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Person-to-person transmission can occur in settings in which there is fecal incontinence and poor hygiene, such as child care centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of acquisition and transmission is greatest for young children who are not yet toilet trained; such children can also serve as a source for secondary cases within their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Giardiasis transmission has also been described among men who have sex with men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/29\">",
"     29",
"    </a>",
"    ]. In one study, anal intercourse was associated with an increased risk for the acquisition of giardiasis among patients with human immunodeficiency virus (HIV) infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Isolate typing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are seven genetic groups (or assemblages) of Giardia; two are found in both humans and animals (A and B) and the remaining five are host specific (C-G) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Genotypes vary within assemblages A and B and it is likely that only some genotypic variants have zoonotic potential. Because of this heterogeneity, the role of animals in the epidemiology of human infection remains poorly understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic variability may also explain the range of clinical manifestations of giardiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Assemblage B isolates appear to occur more frequently in patients with chronic infection than assemblage A isolates. In one study, assemblage A was associated with symptomatic infections and assemblage B was associated with asymptomatic infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/38\">",
"     38",
"    </a>",
"    ]. This association was particularly evident in children under 5 years, suggesting that host factors also influence clinical manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of clinical manifestations associated with giardiasis is variable. In general, about half of exposed individuals clear the infection in the absence of clinical symptoms, and approximately 5 to 15 percent of individuals shed cysts asymptomatically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/39\">",
"     39",
"    </a>",
"    ]. The remaining 35 to 45 percent of individuals have symptomatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/40\">",
"     40",
"    </a>",
"    ]. The nature of clinical manifestations in an individual patient likely depends on a number of factors, including the virulence of the isolate, the parasite load, and the host immune response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Asymptomatic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic infection occurs in both children and adults, and asymptomatic cyst shedding can last six months or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/41\">",
"     41",
"    </a>",
"    ]. In one well-studied outbreak of waterborne giardiasis, two-thirds of those infected were asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/42\">",
"     42",
"    </a>",
"    ]. For this reason, in some circumstances, it may be difficult to recognize a water supply as the common source of giardiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute giardiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of acute giardiasis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diarrhea (sudden in onset; initially may be watery) &mdash; 90 percent",
"     </li>",
"     <li>",
"      Malaise &mdash; 85 percent",
"     </li>",
"     <li>",
"      Foul-smelling and fatty stools (steatorrhea) &mdash; 70 percent",
"     </li>",
"     <li>",
"      Abdominal cramps and bloating &mdash; 70 percent",
"     </li>",
"     <li>",
"      Flatulence &mdash; 75 percent",
"     </li>",
"     <li>",
"      Nausea &mdash; 70 percent",
"     </li>",
"     <li>",
"      Weight loss &mdash; 65 percent",
"     </li>",
"     <li>",
"      Vomiting &mdash; 30 percent",
"     </li>",
"     <li>",
"      Fever &mdash;10 to 15 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms usually develop after an incubation period of 7 to 14 days (range 1 to 45 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/26\">",
"     26",
"    </a>",
"    ]. Symptoms may last two to four weeks. Significant weight loss (10 percent of body weight) occurs in about 50 percent of symptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic giardiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic giardiasis may follow the acute phase of illness or may develop in the absence of an antecedent acute illness. Chronic symptoms can develop in up to half of symptomatic individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/45\">",
"     45",
"    </a>",
"    ]. In one study of experimentally infected individuals, 84 percent had a self limited illness (mean duration 18 days); the remainder became chronically infected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/4,18\">",
"     4,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of chronic giardiasis may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Loose stools but usually not diarrhea",
"     </li>",
"     <li>",
"      Steatorrhea",
"     </li>",
"     <li>",
"      Profound weight loss (10 to 20 percent of body weight)",
"     </li>",
"     <li>",
"      Malabsorption",
"     </li>",
"     <li>",
"      Malaise",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Abdominal cramping",
"     </li>",
"     <li>",
"      Borborygmi",
"     </li>",
"     <li>",
"      Flatulence",
"     </li>",
"     <li>",
"      Burping",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The manifestations may wax and wane over many months.",
"   </p>",
"   <p>",
"    Malabsorption may be responsible for the significant weight loss that can occur in giardiasis. Even in cases of otherwise asymptomatic infection, malabsorption of fats, sugars, carbohydrates and vitamins may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/46\">",
"     46",
"    </a>",
"    ]. This can lead to hypoalbuminemia and deficiencies of vitamin A, B12, and folate.",
"   </p>",
"   <p>",
"    Acquired lactose intolerance occurs in up to 40 percent of patients; clinically, this manifests with exacerbation in intestinal symptoms following ingestion of dairy products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/47\">",
"     47",
"    </a>",
"    ]. Recovery can take many weeks, even after clearance of the parasite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/48-54\">",
"     48-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small number of patients, persistence of infection is associated with development of malabsorption and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/55\">",
"     55",
"    </a>",
"    ]. Chronic giardiasis may resemble other diseases associated with malabsorption, including inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Children with chronic giardiasis present with growth retardation, protuberance of the abdomen, spindly extremities, edema, and pallor. Hypochromic microcytic anemia is common.",
"   </p>",
"   <p>",
"    The effect of chronic giardiasis on growth and development in children is uncertain. One prospective study of 45 Guatemalan children noted an inverse relation between weight gain and severity of giardiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/46\">",
"     46",
"    </a>",
"    ]. Another study among Columbian children suggested that giardiasis was a strong predictor of stunted growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/58\">",
"     58",
"    </a>",
"    ]. A longitudinal study of 597 children in Brazil found that growth was impeded among children with giardiasis, even among those with asymptomatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/59\">",
"     59",
"    </a>",
"    ]. However, other studies have not found a correlation between the presence of Giardia in stools and impaired growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/41,60-62\">",
"     41,60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypersensitivity phenomena such as rash, urticaria, aphthous ulceration, and reactive arthritis or synovitis have been described in the setting of giardiasis, although these manifestations are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, Giardia can spread from the duodenum to the biliary and pancreatic ducts, leading to cholecystitis, cholangitis, or granulomatous hepatitis. Impaired exocrine pancreatic function with diminished secretion of trypsin and lipase has also been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, stool microscopy should be pursued for initial diagnostic evaluation of giardiasis. This test is sensitive and specific for diagnosis of Giardia infection as well as other potential pathogenic causes of the gastrointestinal symptoms described in the preceding sections. Immunoassays have greater sensitivity than stool microscopy and may be used for circumstances in which stool microscopy does not provide a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical tools",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Stool microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, laboratory processing of stool samples for ova and parasite (O&amp;P) examination consists of a saline suspension to look for trophozoites and cysts (",
"    <a class=\"graphic graphic_picture graphicRef50701 \" href=\"mobipreview.htm?32/48/33537\">",
"     picture 1",
"    </a>",
"    ), and a polyvinyl alcohol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    formalin preparation for permanent staining. A loose watery stool is more likely to be positive for trophozoites; a semiformed or formed stool will probably only contain cysts (",
"    <a class=\"graphic graphic_picture graphicRef83430 \" href=\"mobipreview.htm?30/39/31357\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83429 \" href=\"mobipreview.htm?26/42/27297\">",
"     picture 3",
"    </a>",
"    ). Since Giardia is excreted intermittently, in general it can be detected in 50 to 70 percent of cases with a single specimen and in 90 percent of cases after three specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    , antacids, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    interfere with stool microscopy evaluations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Immunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of immunoassays using antibodies against cyst or trophozoite antigens are also available for stool analysis. Available kits include direct immunofluorescent assays (DFA) that use fluorescein-tagged monoclonal antibodies, immunochromatographic assays, and enzyme-linked immunosorbent assays (ELISA). In general, these methods have greater sensitivity and faster turn-around time than conventional stool microscopy methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/65-75\">",
"     65-75",
"    </a>",
"    ]. Specificity and cost are usually relatively comparable. Some studies have shown DFA to have the highest sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/68,76\">",
"     68,76",
"    </a>",
"    ]. Many of the commercially available assays can detect both Giardia and Cryptosporidium simultaneously.",
"   </p>",
"   <p>",
"    One study of 325 stool specimens demonstrated that an ELISA against a specific Giardia antigen (antigen 65) detected 30 percent more cases of Giardia than stool microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/72\">",
"     72",
"    </a>",
"    ]. In a study of stool samples from patients with abdominal symptoms using different assays for detection of Giardia, the sensitivities obtained by Ridascreen Giardia, Rida Quick Giardia, Rida Quick Combi, and Giardia-Strip were 82, 80, 80, and 44 percent, respectively. The specificity of all tests was &ge;98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study that compared stool microscopy, DFA, and three immunodiagnostic techniques for diagnosis of Giardia found that there was agreement among the methods in 76 percent of cases, and that immunologic methods detected more positive results than stool microscopy in 12 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Duodenal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duodenal sampling methods such as duodenal aspiration or biopsy may be useful for cases in which noninvasive tests do not provide definitive diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    for situations in which histopathology of the small bowel would aid in evaluating for alternative diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/64\">",
"     64",
"    </a>",
"    ]. Usually no histopathologic abnormalities are identified in the setting of giardiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/77\">",
"     77",
"    </a>",
"    ]. In some circumstances mild or moderate partial villous atrophy may be observed; in severe cases, subtotal villous atrophy may be observed. An increase in crypt depth may be seen, and microvilli shortening or disruption may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general patients with giardiasis do not have a peripheral leukocytosis or eosinophilia. White cells in stool specimens are usually absent. Fecal fat excretion and other laboratory tests of malabsorption may be abnormal. Upper GI series are usually normal but may demonstrate mucosal edema in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Research tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research tools include serology, culture and polymerase chain reaction (PCR) techniques. Serologic tests are not of value in the diagnosis of acute giardiasis. IgG and IgM antibodies persist after infection so may be useful in epidemiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies utilizing quantitative PCR are facilitating increased understanding of the relationship between infection and clinical disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/36,78-82\">",
"     36,78-82",
"    </a>",
"    ]. In one study using PCR to detect Giardia in stool samples, parasite concentrations as low as 10",
"    <span class=\"nowrap\">",
"     parasites/100",
"    </span>",
"    microL could be detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/80\">",
"     80",
"    </a>",
"    ]. This study also showed 100 percent correlation between PCR, microscopy and ELISA in patients with symptoms suggestive of giardiasis. PCR could also be a valuable tool for screening of water supplies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33224/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/0/28673?source=see_link\">",
"       \"Patient information: Giardia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Giardia lamblia is a protozoan parasite capable of causing epidemic or sporadic diarrheal illness. It has two morphological forms: cysts and trophozoites. Cysts are the infectious form of the parasite; following cyst ingestion, trophozoites are released in the proximal small intestine. Trophozoites that do not adhere to the small intestine move forward to the large intestine where they revert to the infectious cyst form; these cysts are passed back into the environment in excreted feces. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Life cycle and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      G. lamblia infection occurs worldwide. High risk groups include infants, young children, international adoptees, travelers, immunocompromised individuals, and patients with hypochlorhydria or cystic fibrosis. Giardiasis is especially common in areas with poor sanitary conditions and insufficient water treatment facilities. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Giardia cysts may be transmitted via water, food or fecal-oral transmission between infected individuals. Giardiasis is an important cause of diarrheal illness among hikers in wilderness areas who drink water that has not been adequately filtered, treated or boiled. Transmission of giardiasis can also occur with ingestion of raw or undercooked food contaminated with cysts or food that is contaminated following cooking. Person to person transmission can occur in settings in which there is fecal incontinence and poor hygiene, such as child care centers. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Routes of transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of clinical manifestations associated with giardiasis is variable. In general, about half of exposed individuals clear the infection in the absence of clinical symptoms and approximately 5 to 15 percent of individuals shed cysts asymptomatically. The remaining 35 to 45 percent of individuals develop symptomatic infection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of acute giardiasis include diarrhea, malaise, abdominal cramps and weight loss. Malabsorption may be responsible for the significant weight loss that can occur in giardiasis. Acquired lactose intolerance occurs in up to 40 percent of patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Acute giardiasis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Chronic giardiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial diagnostic evaluation of giardiasis should consist of stool microscopy; this test is sensitive and specific for diagnosis of Giardia infection as well as other potential pathogenic causes of gastrointestinal symptoms. Immunoassays have greater sensitivity than stool microscopy and may be used for circumstances in which stool microscopy does not provide a definitive diagnosis. Duodenal histopathology is usually normal in the setting of giardiasis; in some cases villous atrophy may be observed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/1\">",
"      Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/2\">",
"      Kappus KD, Lundgren RG Jr, Juranek DD, et al. Intestinal parasitism in the United States: update on a continuing problem. Am J Trop Med Hyg 1994; 50:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/3\">",
"      Musher DM, Musher BL. Contagious acute gastrointestinal infections. N Engl J Med 2004; 351:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/4\">",
"      RENDTORFF RC. The experimental transmission of human intestinal protozoan parasites. II. Giardia lamblia cysts given in capsules. Am J Hyg 1954; 59:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/5\">",
"      Halliday CE, Inge PM, Farthing MJ. Characterization of bile salt uptake by Giardia lamblia. Int J Parasitol 1995; 25:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/6\">",
"      Buret AG. Pathophysiology of enteric infections with Giardia duodenalius. Parasite 2008; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/7\">",
"      Gilman RH, Brown KH, Visvesvara GS, et al. Epidemiology and serology of Giardia lamblia in a developing country: Bangladesh. Trans R Soc Trop Med Hyg 1985; 79:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/8\">",
"      Istre GR, Dunlop TS, Gaspard GB, Hopkins RS. Waterborne giardiasis at a mountain resort: evidence for acquired immunity. Am J Public Health 1984; 74:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/9\">",
"      Lai Ping So A, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastrointest Dis 1997; 8:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/10\">",
"      Smith PD, Lane HC, Gill VJ, et al. Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. Ann Intern Med 1988; 108:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/11\">",
"      Stark D, Barratt JL, van Hal S, et al. Clinical significance of enteric protozoa in the immunosuppressed human population. Clin Microbiol Rev 2009; 22:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/12\">",
"      Roberts DM, Craft JC, Mather FJ, et al. Prevalence of giardiasis in patients with cystic fibrosis. J Pediatr 1988; 112:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/13\">",
"      Mason PR, Patterson BA. Epidemiology of Giardia lamblia infection in children: cross-sectional and longitudinal studies in urban and rural communities in Zimbabwe. Am J Trop Med Hyg 1987; 37:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/14\">",
"      Curtale F, Nabil M, el Wakeel A, Shamy MY. Anaemia and intestinal parasitic infections among school age children in Behera Governorate, Egypt. Behera Survey Team. J Trop Pediatr 1998; 44:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/15\">",
"      Cooper MA, Sterling CR, Gilman RH, et al. Molecular analysis of household transmission of Giardia lamblia in a region of high endemicity in Peru. J Infect Dis 2010; 202:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/16\">",
"      Yoder JS, Gargano JW, Wallace RM, et al. Giardiasis surveillance--United States, 2009-2010. MMWR Surveill Summ 2012; 61:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/17\">",
"      Greig JD, Michel P, Wilson JB, et al. A descriptive analysis of giardiasis cases reported in Ontario, 1990-1998. Can J Public Health 2001; 92:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/18\">",
"      Caeiro JP, Mathewson JJ, Smith MA, et al. Etiology of outpatient pediatric nondysenteric diarrhea: a multicenter study in the United States. Pediatr Infect Dis J 1999; 18:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/19\">",
"      Sagebiel D, Weitzel T, Stark K, Leitmeyer K. Giardiasis in kindergartens: prevalence study in Berlin, Germany, 2006. Parasitol Res 2009; 105:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/20\">",
"      Saiman L, Aronson J, Zhou J, et al. Prevalence of infectious diseases among internationally adopted children. Pediatrics 2001; 108:608.",
"     </a>",
"    </li>",
"    <li>",
"     Hill DR, Nash TE. Intestinal flagellate and ciliate infections. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 2nd, Guerrant RL, Walker DA, Weller PF (Eds), WB Saunders, Philadelphia 1999. p.623.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/22\">",
"      Chute CG, Smith RP, Baron JA. Risk factors for endemic giardiasis. Am J Public Health 1987; 77:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/23\">",
"      Wallis PM, Erlandsen SL, Isaac-Renton JL, et al. Prevalence of Giardia cysts and Cryptosporidium oocysts and characterization of Giardia spp. isolated from drinking water in Canada. Appl Environ Microbiol 1996; 62:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/24\">",
"      Dykes AC, Juranek DD, Lorenz RA, et al. Municipal waterborne giardiasis: an epidemilogic investigation. Beavers implicated as a possible reservoir. Ann Intern Med 1980; 92:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/25\">",
"      Mintz ED, Hudson-Wragg M, Mshar P, et al. Foodborne giardiasis in a corporate office setting. J Infect Dis 1993; 167:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/26\">",
"      Quick R, Paugh K, Addiss D, et al. Restaurant-associated outbreak of giardiasis. J Infect Dis 1992; 166:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/27\">",
"      Okhuysen PC. Traveler's diarrhea due to intestinal protozoa. Clin Infect Dis 2001; 33:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/28\">",
"      Overturf GD. Endemic giardiasis in the United States--role of the daycare center. Clin Infect Dis 1994; 18:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/29\">",
"      Moldwin RM. Sexually transmitted protozoal infections. Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia. Urol Clin North Am 1992; 19:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/30\">",
"      Esfandiari A, Jordan WC, Brown CP. Prevalence of enteric parasitic infection among HIV-infected attendees of an inner city AIDS clinic. Cell Mol Biol (Noisy-le-grand) 1995; 41 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/31\">",
"      Cacci&ograve; SM, Ryan U. Molecular epidemiology of giardiasis. Mol Biochem Parasitol 2008; 160:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/32\">",
"      Volot&atilde;o AC, Costa-Macedo LM, Haddad FS, et al. Genotyping of Giardia duodenalis from human and animal samples from Brazil using beta-giardin gene: a phylogenetic analysis. Acta Trop 2007; 102:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/33\">",
"      Sprong H, Cacci&ograve; SM, van der Giessen JW, ZOOPNET network and partners. Identification of zoonotic genotypes of Giardia duodenalis. PLoS Negl Trop Dis 2009; 3:e558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/34\">",
"      Franz&eacute;n O, Jerlstr&ouml;m-Hultqvist J, Castro E, et al. Draft genome sequencing of giardia intestinalis assemblage B isolate GS: is human giardiasis caused by two different species? PLoS Pathog 2009; 5:e1000560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/35\">",
"      Ortega-Pierres G, Smith HV, Cacci&ograve; SM, Thompson RC. New tools provide further insights into Giardia and Cryptosporidium biology. Trends Parasitol 2009; 25:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/36\">",
"      Thompson RC. Echinococcus, Giardia and Cryptosporidium: observational studies challenging accepted dogma. Parasitology 2009; 136:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/37\">",
"      Monis PT, Caccio SM, Thompson RC. Variation in Giardia: towards a taxonomic revision of the genus. Trends Parasitol 2009; 25:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/38\">",
"      Sahag&uacute;n J, Clavel A, Go&ntilde;i P, et al. Correlation between the presence of symptoms and the Giardia duodenalis genotype. Eur J Clin Microbiol Infect Dis 2008; 27:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/39\">",
"      Nash TE, Herrington DA, Losonsky GA, Levine MM. Experimental human infections with Giardia lamblia. J Infect Dis 1987; 156:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/40\">",
"      Ali SA, Hill DR. Giardia intestinalis. Curr Opin Infect Dis 2003; 16:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/41\">",
"      Pickering LK, Woodward WE, DuPont HL, Sullivan P. Occurrence of Giardia lamblia in children in day care centers. J Pediatr 1984; 104:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/42\">",
"      L&oacute;pez CE, Dykes AC, Juranek DD, et al. Waterborne giardiasis: a communitywide outbreak of disease and a high rate of asymptomatic infection. Am J Epidemiol 1980; 112:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/43\">",
"      Brodsky RE, Spencer HC Jr, Schultz MG. Giardiasis in American travelers to the Soviet Union. J Infect Dis 1974; 130:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/44\">",
"      Hopkins RS, Juranek DD. Acute giardiasis: an improved clinical case definition for epidemiologic studies. Am J Epidemiol 1991; 133:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/45\">",
"      Cantey PT, Roy S, Lee B, et al. Study of nonoutbreak giardiasis: novel findings and implications for research. Am J Med 2011; 124:1175.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/46\">",
"      Ortega YR, Adam RD. Giardia: overview and update. Clin Infect Dis 1997; 25:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/47\">",
"      Hill DR. Giardiasis. Issues in diagnosis and management. Infect Dis Clin North Am 1993; 7:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/48\">",
"      Farthing MJ. Giardiasis. Gastroenterol Clin North Am 1996; 25:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/49\">",
"      Singh KD, Bhasin DK, Rana SV, et al. Effect of Giardia lamblia on duodenal disaccharidase levels in humans. Trop Gastroenterol 2000; 21:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/50\">",
"      Ish-Horowicz M, Korman SH, Shapiro M, et al. Asymptomatic giardiasis in children. Pediatr Infect Dis J 1989; 8:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/51\">",
"      Grazioli B, Matera G, Laratta C, et al. Giardia lamblia infection in patients with irritable bowel syndrome and dyspepsia: a prospective study. World J Gastroenterol 2006; 12:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/52\">",
"      Rana SV, Bhasin DK, Vinayak VK. Lactose hydrogen breath test in Giardia lamblia-positive patients. Dig Dis Sci 2005; 50:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/53\">",
"      Pettoello Mantovani M, Guandalini S, Ecuba P, et al. Lactose malabsorption in children with symptomatic Giardia lamblia infection: feasibility of yogurt supplementation. J Pediatr Gastroenterol Nutr 1989; 9:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/54\">",
"      Vega-Franco L, Meza C, Romero JL, et al. Breath hydrogen test in children with giardiasis. J Pediatr Gastroenterol Nutr 1987; 6:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/55\">",
"      Lengerich EJ, Addiss DG, Juranek DD. Severe giardiasis in the United States. Clin Infect Dis 1994; 18:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/56\">",
"      Bai JC. Malabsorption syndromes. Digestion 1998; 59:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/57\">",
"      Gunasekaran TS, Hassall E. Giardiasis mimicking inflammatory bowel disease. J Pediatr 1992; 120:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/58\">",
"      Botero-Garc&eacute;s JH, Garc&iacute;a-Montoya GM, Grisales-Pati&ntilde;o D, et al. Giardia intestinalis and nutritional status in children participating in the complementary nutrition program, Antioquia, Colombia, May to October 2006. Rev Inst Med Trop Sao Paulo 2009; 51:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/59\">",
"      Prado MS, Cairncross S, Strina A, et al. Asymptomatic giardiasis and growth in young children; a longitudinal study in Salvador, Brazil. Parasitology 2005; 131:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/60\">",
"      Farthing MJ, Mata L, Urrutia JJ, Kronmal RA. Natural history of Giardia infection of infants and children in rural Guatemala and its impact on physical growth. Am J Clin Nutr 1986; 43:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/61\">",
"      Silva RR, da Silva CA, de Jesus Pereira CA, et al. Association between nutritional status, environmental and socio-economic factors and Giardia lamblia infections among children aged 6-71 months in Brazil. Trans R Soc Trop Med Hyg 2009; 103:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/62\">",
"      Hollm-Delgado MG, Gilman RH, Bern C, et al. Lack of an adverse effect of Giardia intestinalis infection on the health of Peruvian children. Am J Epidemiol 2008; 168:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/63\">",
"      Hiatt RA, Markell EK, Ng E. How many stool examinations are necessary to detect pathogenic intestinal protozoa? Am J Trop Med Hyg 1995; 53:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/64\">",
"      Goka AK, Rolston DD, Mathan VI, Farthing MJ. The relative merits of faecal and duodenal juice microscopy in the diagnosis of giardiasis. Trans R Soc Trop Med Hyg 1990; 84:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/65\">",
"      Aldeen WE, Hale D, Robison AJ, Carroll K. Evaluation of a commercially available ELISA assay for detection of Giardia lamblia in fecal specimens. Diagn Microbiol Infect Dis 1995; 21:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/66\">",
"      Winiecka-Krusnell J, Linder E. Detection of Giardia lamblia cysts in stool samples by immunofluorescence using monoclonal antibody. Eur J Clin Microbiol Infect Dis 1995; 14:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/67\">",
"      Zimmerman SK, Needham CA. Comparison of conventional stool concentration and preserved-smear methods with Merifluor Cryptosporidium/Giardia Direct Immunofluorescence Assay and ProSpecT Giardia EZ Microplate Assay for detection of Giardia lamblia. J Clin Microbiol 1995; 33:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/68\">",
"      Garcia LS, Shimizu RY. Evaluation of nine immunoassay kits (enzyme immunoassay and direct fluorescence) for detection of Giardia lamblia and Cryptosporidium parvum in human fecal specimens. J Clin Microbiol 1997; 35:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/69\">",
"      Katanik MT, Schneider SK, Rosenblatt JE, et al. Evaluation of ColorPAC Giardia/Cryptosporidium rapid assay and ProSpecT Giardia/Cryptosporidium microplate assay for detection of Giardia and Cryptosporidium in fecal specimens. J Clin Microbiol 2001; 39:4523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/70\">",
"      Duque-Beltr&aacute;n S, Nicholls-Orejuela RS, Ar&eacute;valo-Jamaica A, et al. Detection of Giardia duodenalis antigen in human fecal eluates by enzyme-linked immunosorbent assay using polyclonal antibodies. Mem Inst Oswaldo Cruz 2002; 97:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/71\">",
"      Garcia LS, Garcia JP. Detection of Giardia lamblia antigens in human fecal specimens by a solid-phase qualitative immunochromatographic assay. J Clin Microbiol 2006; 44:4587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/72\">",
"      Rosoff JD, Sanders CA, Sonnad SS, et al. Stool diagnosis of giardiasis using a commercially available enzyme immunoassay to detect Giardia-specific antigen 65 (GSA 65). J Clin Microbiol 1989; 27:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/73\">",
"      Weitzel T, Dittrich S, M&ouml;hl I, et al. Evaluation of seven commercial antigen detection tests for Giardia and Cryptosporidium in stool samples. Clin Microbiol Infect 2006; 12:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/74\">",
"      Aziz H, Beck CE, Lux MF, Hudson MJ. A comparison study of different methods used in the detection of Giardia lamblia. Clin Lab Sci 2001; 14:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/75\">",
"      Hanson KL, Cartwright CP. Use of an enzyme immunoassay does not eliminate the need to analyze multiple stool specimens for sensitive detection of Giardia lamblia. J Clin Microbiol 2001; 39:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/76\">",
"      Al FD, Kutimur S, Ozekinci T, et al. The use of enzyme linked immunosorbent assay (ELISA) and direct fluorescent antibody (DFA) methods for diagnosis of Giardia intestinalis. Turkiye Parazitol Derg 2006; 30:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/77\">",
"      Oberhuber G, Kastner N, Stolte M. Giardiasis: a histologic analysis of 567 cases. Scand J Gastroenterol 1997; 32:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/78\">",
"      Helmy MM, Abdel-Fattah HS, Rashed L. Real-time PCR/RFLP assay to detect Giardia intestinalis genotypes in human isolates with diarrhea in Egypt. J Parasitol 2009; 95:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/79\">",
"      Eligio-Garc&iacute;a L, Cort&eacute;s-Campos A, Jim&eacute;nez-Cardoso E. Classification of Giardia intestinalis isolates by multiple polymerase chain reaction (multiplex). Parasitol Res 2008; 103:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/80\">",
"      Ghosh S, Debnath A, Sil A, et al. PCR detection of Giardia lamblia in stool: targeting intergenic spacer region of multicopy rRNA gene. Mol Cell Probes 2000; 14:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/81\">",
"      Nantavisai K, Mungthin M, Tan-ariya P, et al. Evaluation of the sensitivities of DNA extraction and PCR methods for detection of Giardia duodenalis in stool specimens. J Clin Microbiol 2007; 45:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/82\">",
"      Schuurman T, Lankamp P, van Belkum A, et al. Comparison of microscopy, real-time PCR and a rapid immunoassay for the detection of Giardia lamblia in human stool specimens. Clin Microbiol Infect 2007; 13:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33224/abstract/83\">",
"      Mayer CL, Palmer CJ. Evaluation of PCR, nested PCR, and fluorescent antibodies for detection of Giardia and Cryptosporidium species in wastewater. Appl Environ Microbiol 1996; 62:2081.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5723 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33224=[""].join("\n");
var outline_f32_28_33224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIFE CYCLE AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Routes of transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Isolate typing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Asymptomatic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute giardiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic giardiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical tools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Stool microscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Immunoassays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Duodenal biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Research tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5723\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5723|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/48/33537\" title=\"picture 1\">",
"      Giardia trophozoite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/39/31357\" title=\"picture 2\">",
"      Giardia cyst - iodine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/42/27297\" title=\"picture 3\">",
"      Giardia cyst - trichrome stain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/0/28673?source=related_link\">",
"      Patient information: Giardia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6424?source=related_link\">",
"      Treatment and prevention of giardiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_28_33225="Varicella-zoster virus infection in pregnancy";
var content_f32_28_33225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Varicella-zoster virus infection in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33225/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33225/contributors\">",
"     Laura E Riley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33225/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33225/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33225/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33225/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/28/33225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H234396\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) is one of eight herpesviruses known to cause human infection worldwide. Varicella infection in children is generally a mild disease, while infection in adults can lead to significant morbidity and mortality. During pregnancy, varicella pneumonia can be particularly severe and maternal infection can lead to congenital abnormalities with devastating consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address the epidemiology, infectious complications, management and prevention of varicella in the pregnant female. The clinical manifestations, treatment and prevention of VZV infection in the nonpregnant adult are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of the newborn who has been exposed to varicella is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=see_link\">",
"     \"Varicella-zoster infection in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2091972\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2092079\">",
"    <span class=\"h2\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary VZV infection results in the diffuse vesicular rash of varicella, or chickenpox. Primary infection with VZV during pregnancy has significant implications for maternal and fetal health:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although fewer than 2 percent of reported cases of varicella infections occur among adults older than 20 years of age, almost a quarter of all VZV-related mortality occurs among this age group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/2\">",
"       2",
"      </a>",
"      ]. Thus, pregnant women are at risk for substantial morbidity and mortality.",
"     </li>",
"     <li>",
"      If the mother acquires varicella infection during the early gestational period (weeks 8 to 20), the fetus is at risk for developing congenital varicella syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3\">",
"       3",
"      </a>",
"      ]. This syndrome is characterized by limb hypoplasia, skin lesions, neurologic abnormalities, and structural eye damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features of congenital varicella syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Maternal varicella during pregnancy is also associated with the subsequent development of herpes zoster during infancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the mother acquires varicella immediately before or after delivery, the baby is at risk for neonatal varicella, which may present with mild rash to disseminated infection. Neonatal disease is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=see_link\">",
"       \"Varicella-zoster infection in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2092072\">",
"    <span class=\"h2\">",
"     Herpes zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous reactivation of latent VZV typically results in a localized skin infection known as herpes zoster, or shingles. Maternal herpes zoster infection is not associated with a significant risk of congenital varicella syndrome, although maternal varicella with subsequent embryopathy has been described in one case report where the pregnant mother touched vesicular fluid on the scalp of a person with zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2091913\">",
"     'Congenital varicella'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24973924\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall trends in the epidemiology of VZV infection are changing in light of the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in 1995. However, the incidence of varicella is not precisely known since it is not a reportable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2091906\">",
"    <span class=\"h2\">",
"     Maternal varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 1980s, the incidence of maternal varicella was estimated at 1 to 5 cases per 10,000 pregnancies in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/5\">",
"     5",
"    </a>",
"    ]. This low incidence is related to the high rates of VZV seropositivity among adults (&gt;95 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ]. Similar rates have been demonstrated in Europe, but VZV seropositivity rates among persons living in tropical areas are lower, at approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Although the incidence of varicella is not higher in pregnant compared to nonpregnant adults, disease severity appears to be increased, with varicella pneumonia complicating 10 to 20 percent of maternal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/2\">",
"     2",
"    </a>",
"    ]. Prior to the introduction of effective antiviral therapy, the morbidity and mortality related to varicella pneumonia was estimated at 20 to 45 percent, and has remained significant at 3 to 14 percent in the era of antiviral treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ]. Risk factors for varicella pneumonia during pregnancy include a history of smoking and having greater than 100 cutaneous vesicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/2,11\">",
"     2,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2091913\">",
"    <span class=\"h2\">",
"     Congenital varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nine observational studies performed between 1986 and 2002 suggest that congenital varicella syndrome is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Fewer than 2 percent of women who have acquired varicella infection during the first 20 weeks of gestation have subsequently given birth to an infant with this embryopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3,4,13,14,16\">",
"     3,4,13,14,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest published prospective study of 1739 cases of maternal varicella infection, the incidence of congenital abnormalities was 0.4 percent if maternal infection occurred before the 12th week of pregnancy; the risk increased to approximately two percent if maternal infection occurred between weeks 13 and 20 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 362 women with maternal VZV infection (347 with varicella; 15 with zoster), only one female with varicella infection gave birth to an infant with VZV embryopathy (0.4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Only nine isolated cases of congenital varicella have been reported between weeks 21 to 28 of gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the largest published prospective study of maternal varicella, there were 344 cases of herpes zoster and there were no cases of congenital varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3\">",
"     3",
"    </a>",
"    ]. However, there is one case report from 1987 of congenital varicella syndrome following maternal zoster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234536\">",
"    <span class=\"h2\">",
"     Effect of varicella vaccine on VZV epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of varicella has changed over time since the introduction of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in 1995. High immunization rates with one dose of varicella vaccine led to an 84 percent reduction in the number of varicella cases in the United States and an 88 percent decline in varicella-related hospitalizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/19\">",
"     19",
"    </a>",
"    ]. Despite these improvements, varicella-related infections and breakthrough varicella disease were reported, leading to the initiation of a two-dose schedule in 2006. The vaccine efficacy of two doses over a 10-year observation period is estimated at 98 percent for the prevention of any infection and 100 percent for the prevention of severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A US-based survey demonstrated that the incidence of varicella infections among adults has declined by 74 percent in the decade following the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/20\">",
"     20",
"    </a>",
"    ]. Since only 3 percent of the adults surveyed had been vaccinated, the substantial decline of infections was attributed to herd immunity. Although the incidence data showed a positive impact of immunization, adults who developed varicella were at higher risk of morbidity and mortality compared with children.",
"   </p>",
"   <p>",
"    Epidemiologic data also suggest that varicella vaccination has reduced the number of maternal and fetal varicella infections. As an example, surveillance data from Australia from 2006 to 2009 demonstrated that the incidence of congenital varicella infection was 0.19 per 100,000 live",
"    <span class=\"nowrap\">",
"     births/annum",
"    </span>",
"    and the incidence of neonatal infection was 2 per 100,000 live",
"    <span class=\"nowrap\">",
"     births/annum",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/21\">",
"     21",
"    </a>",
"    ]. These trends represent an 85 percent reduction in varicella cases among newborns in the post-vaccination era compared to the prevaccination era.",
"   </p>",
"   <p>",
"    No long-term data are available on the duration of protection of the two-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2091920\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the risk of transmission of VZV infection is higher with exposure to varicella compared with zoster. Persons with either illness are not considered infectious once lesions have crusted over.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2091946\">",
"    <span class=\"h2\">",
"     Person to person",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella is highly communicable with secondary attack rates in susceptible household contacts approaching 90 percent in the prevaccination era [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients are infectious from one to two days prior to this rash until the lesions are crusted over.",
"   </p>",
"   <p>",
"    Varicella is usually transmitted by infected secretions harbored in the nasopharyngeal mucosa by droplets onto the conjunctival or",
"    <span class=\"nowrap\">",
"     nasal/oral",
"    </span>",
"    mucosa. Other mechanisms include direct contact with vesicular fluids that contain virus, and rarely, the airborne spread of virus.",
"   </p>",
"   <p>",
"    Susceptible persons can also acquire varicella infection from exposure to persons with zoster, although the transmission rates are considerably lower and usually require close exposure to open cutaneous lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2091964\">",
"    <span class=\"h2\">",
"     Mother to infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal varicella infection not only has important implications for the mother&rsquo;s health, but also for her fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ]. Transmission can occur in utero, perinatally, or postnatally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/24\">",
"     24",
"    </a>",
"    ]. Intrauterine or perinatal infection of the fetus is facilitated through transplacental transmission while postnatal varicella is transmitted through respiratory droplets or direct contact with someone with varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Passage of varicella zoster virus to the fetus during zoster is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3,14,25\">",
"     3,14,25",
"    </a>",
"    ]. The low observed rates of transmission may be related to preexisting maternal antibody to VZV and to the generally lower levels of viremia that accompany reactivation of VZV infection (eg, shingles) compared with primary infection (eg, chickenpox) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2092125\">",
"    <span class=\"h1\">",
"     INCUBATION PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period of varicella in an adult or child is 10 to 21 days after exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans are the only source of VZV infection. Primary varicella infection generally leads to lifelong immunity; case reports of reinfections are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2092086\">",
"    <span class=\"h2\">",
"     Maternal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infection is followed by viral replication in regional lymph nodes and tonsils and possibly ductal tissue of salivary glands for four to six days with subsequent spread to other internal organs. After continued replication, VZV is again released into the bloodstream (secondary viremia) and invades cutaneous tissue resulting in the VZV exanthem within approximately 14 to 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     In utero infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism of in utero VZV infection is unknown. It is widely accepted that maternal viremia leads to placental infection with subsequent fetal infection; thus, prevention of maternal infection is of high priority. VZV DNA may be detected in multiple fetal organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/29\">",
"     29",
"    </a>",
"    ]; histologic examination of the placenta demonstrates granulomas and acute inflammation.",
"   </p>",
"   <p>",
"    The sites of VZV replication in the fetus are unclear. It has been suggested that the fetus develops varicella in utero followed by resolution and subsequent infection of the dorsal root ganglia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/18\">",
"     18",
"    </a>",
"    ]. This results in cell destruction in nerve tissue, which may account for limb denervation changes seen in the congenital varicella syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF MATERNAL VZV INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2092264\">",
"    <span class=\"h2\">",
"     Uncomplicated varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic rash of varicella, which is usually pruritic, appears in successive crops of vesicles on the face, trunk and extremities. Thus, the patient with varicella typically has lesions in different stages of development. New vesicle formation generally stops within four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/30\">",
"     30",
"    </a>",
"    ]. Many patients with uncomplicated varicella experience a prodrome of fever, malaise, and myalgia one to four days prior to the onset of rash.",
"   </p>",
"   <p>",
"    The lesions begin as macules that rapidly become papules followed by vesicles (",
"    <a class=\"graphic graphic_picture graphicRef55533 \" href=\"mobipreview.htm?36/3/36927\">",
"     picture 1",
"    </a>",
"    ). These lesions can then develop a pustular component followed by the formation of crusted papules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/31\">",
"     31",
"    </a>",
"    ]. Most lesions have fully crusted by day six in normal hosts. Crusts tend to fall off within about one to two weeks and leave a temporary area of hypopigmentation in the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2092271\">",
"    <span class=\"h2\">",
"     Complicated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-related complications are more common in adults than children and include meningitis, encephalitis, cerebellar ataxia, pneumonia, glomerulonephritis, myocarditis, ocular disease, adrenal insufficiency, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/32\">",
"     32",
"    </a>",
"    ]. Secondary bacterial infections can also occur in patients with significant cutaneous disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Varicella pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical manifestation of complicated varicella infection in pregnancy is varicella pneumonia, although the overall incidence is low at 0.7 to 3 per 1000 pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The predominant signs and symptoms of varicella pneumonia in pregnancy are cough, dyspnea, fever, and tachypnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/26,33\">",
"     26,33",
"    </a>",
"    ]. The pneumonia usually develops within one week of the rash. The clinical course is unpredictable and may rapidly progress to hypoxia and respiratory failure. The chest x-ray findings include a diffuse or",
"    <span class=\"nowrap\">",
"     miliary/nodular",
"    </span>",
"    infiltrative pattern often in the peribronchial distribution involving both lungs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FETAL EFFECTS OF VZV INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical features of congenital varicella syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital varicella syndrome, first described in 1947, is characterized by the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/9,34-36\">",
"     9,34-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous scars in a dermatomal pattern",
"     </li>",
"     <li>",
"      Neurological abnormalities (eg, mental retardation, microcephaly, hydrocephalus, seizures, Horner&rsquo;s syndrome)",
"     </li>",
"     <li>",
"      Ocular abnormalities (eg, optic nerve atrophy, cataracts, chorioretinitis, microphthalmos, nystagmus)",
"     </li>",
"     <li>",
"      Limb abnormalities (hypoplasia, atrophy, paresis)",
"     </li>",
"     <li>",
"      Gastrointestinal abnormalities (gastroesophageal reflux, atretic or stenotic bowel)",
"     </li>",
"     <li>",
"      Low birth weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Congenital varicella syndrome is associated with a mortality rate of 30 percent in the first few months of life and a 15 percent risk of developing herpes zoster in the first four years of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1098652\">",
"    <span class=\"h2\">",
"     Prematurity and spontaneous abortion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella is not generally associated with first-trimester spontaneous abortions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/1\">",
"     1",
"    </a>",
"    ]. In several cohort studies, no significant differences in spontaneous abortion rates, premature births, or intrauterine death were noted between the maternal varicella group and the control group, although the overall number of mothers with varicella infection was small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/13,37-39\">",
"     13,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neonatal VZV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal varicella infection results from VZV transmission from a mother to the fetus just prior to delivery. Neonates born to mothers who have clinical disease within five days before to two days after delivery are at the greatest risk for severe disease and poor outcome. Management of the newborn with varicella exposure and varicella infection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=see_link\">",
"     \"Varicella-zoster infection in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1098780\">",
"    <span class=\"h2\">",
"     Maternal varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of varicella infection is clinical. If there is doubt about the clinical diagnosis, VZV infection may be rapidly confirmed through detection of viral DNA by PCR testing of skin scrapings from the base of the vesicle or through the detection of VZV antigen by immunofluorescence. VZV can also be cultured from vesicular fluid, although the virus replicates slowly and culture is less sensitive than direct detection techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/77?source=see_link\">",
"     \"Diagnosis of varicella-zoster virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serologic testing is usually not necessary for diagnosis of maternal varicella, and may be potentially confusing since the assays vary in sensitivity and specificity. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1098827\">",
"    <span class=\"h2\">",
"     Congenital varicella syndrome",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2130642\">",
"    <span class=\"h3\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;After maternal infection, the risk of congenital varicella syndrome can be estimated using polymerase chain reaction (PCR) testing of fetal blood or amniotic fluid for VZV DNA in conjunction with ultrasonography for detection of fetal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/9,36,40,41\">",
"     9,36,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCR testing for VZV DNA is a sensitive test, which is usually obtained between 17 and 21 weeks of gestation. A detailed anatomic ultrasound evaluation should occur at a minimum of five weeks after maternal infection to assess fetal abnormalities consistent with congenital varicella syndrome (eg, microcephaly, limb hypoplasia, intrauterine growth retardation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal results of imaging and laboratory testing suggest a low risk of congenital varicella syndrome. A normal ultrasound with detectable VZV DNA suggests potential risk; thus, a repeat ultrasound at 22 to 24 weeks is indicated. If the repeat ultrasound is normal, the risk of congenital varicella syndrome is remote. If the ultrasound shows evidence of congenital varicella syndrome, the woman should be counseled regarding likely fetal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic testing of the fetus is of limited utility because of low sensitivity and poor specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3,25,36,41\">",
"     3,25,36,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2130764\">",
"    <span class=\"h3\">",
"     Postnatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of congenital varicella syndrome requires the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/1,43\">",
"     1,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of maternal varicella infection during the first or second trimester of pregnancy",
"     </li>",
"     <li>",
"      Presence of compatible fetal abnormalities consistent with congenital varicella syndrome",
"     </li>",
"     <li>",
"      Evidence of intrauterine VZV infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence of intrauterine infection can include any of the following: detection of VZV DNA in the newborn; presence of VZV-specific IgM antibodies in cord blood; persistence of VZV IgG beyond seven months of age; appearance of clinical zoster infection during early infancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF MATERNAL VZV INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment of varicella infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259842\">",
"    <span class=\"h3\">",
"     Uncomplicated varicella infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized placebo-controlled trial in male and nonpregnant female adults with primary varicella infection evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    within 72 hours of symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/44\">",
"     44",
"    </a>",
"    ]. The trial demonstrated that acyclovir treatment was associated with faster healing of skin lesions and a shorter duration of fever, if initiated within 24 hours of symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/44\">",
"     44",
"    </a>",
"    ]. The low frequency of complicated infections (eg, varicella pneumonia) in the study population precluded evaluation of any effect of acyclovir on more severe disease.",
"   </p>",
"   <p>",
"    The use of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for uncomplicated varicella infection among pregnant women has not been studied. Although animal data and observational data from large pregnancy registries do not suggest teratogenicity of acyclovir, well-controlled studies have not been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/17\">",
"     17",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP) does not recommend routine use of acyclovir for uncomplicated varicella infection in pregnant women due to the concern about safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/17\">",
"     17",
"    </a>",
"    ]. However, a prospective registry of acyclovir-exposed pregnancies revealed no increased rate of birth defects or pattern of birth defects in 596 infants who were followed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, we suggest oral acyclovir therapy (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    PO four times daily for five days) for all pregnant women with uncomplicated varicella. A woman who is a secondary contact of a patient with varicella is of particular concern since secondary cases are more likely to have more severe disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\", section on 'Clinical manifestations'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259849\">",
"    <span class=\"h3\">",
"     Varicella pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella pneumonia during pregnancy is a medical emergency; the mortality rate among pregnant women in the era prior to antiviral therapy approximated 36 to 40 percent in case series reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/33,46,47\">",
"     33,46,47",
"    </a>",
"    ]. Although there are no randomized controlled trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    for the treatment of varicella pneumonia, observational data suggest a beneficial impact of antiviral therapy on maternal mortality when compared with historical controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/11,33,47-49\">",
"     11,33,47-49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 21 cases of varicella pneumonia in pregnant women treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      , the mortality rate was 14 percent, a value lower than expected in untreated women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study, all 18 patients with varicella pneumonia, who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      , survived [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/11\">",
"       11",
"      </a>",
"      ]. Twelve patients required intubation and mechanical ventilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours) for pregnant women with varicella pneumonia. The risk-benefit of treatment of maternal varicella infection outweighs any theoretical concerns regarding fetal toxicity; no specific pattern of congenital malformations has been attributed to acyclovir in large pregnancy registries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    crosses the placenta, it is unknown if this antiviral agent decreases the risk of congenital varicella syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment of herpes zoster infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of herpes zoster during pregnancy is similar to that in nonpregnant adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=see_link&amp;anchor=H1867100#H1867100\">",
"     \"Treatment of herpes zoster in the immunocompetent host\", section on 'Herpes zoster during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24974620\">",
"    <span class=\"h1\">",
"     POST-EXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention is targeted to susceptible hosts who do not have a history of infection or serologic evidence of prior exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3722805\">",
"    <span class=\"h2\">",
"     Evaluating susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;A self-reported history of varicella among pregnant women is a powerful predictor of antibodies to varicella infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, most women without a history of varicella have serologic evidence of past infection.",
"   </p>",
"   <p>",
"    These concepts were well-illustrated in a study of pregnant females where more than 98 percent of 838 pregnant females with a history of varicella infection had serologic evidence of past infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, only a minority of women, who reported a negative or uncertain history of varicella, was subsequently confirmed to be seronegative for varicella antibodies (ie, 7 and 17 percent, respectively).",
"   </p>",
"   <p>",
"    Ideally, a VZV serologic test should be conducted prior to administration of immunoprophylaxis among those women who report no history of varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/52\">",
"     52",
"    </a>",
"    ]; such a strategy is cost-effective and suggested by some experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. However, rapid screening is necessary since prophylaxis should be offered within ten days of exposure. If results of serologic testing are not available within this time frame, then postexposure prophylaxis should be offered.",
"   </p>",
"   <p>",
"    Evidence of immunity is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=see_link\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260293\">",
"    <span class=\"h2\">",
"     Defining exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among nonimmune pregnant women, it is important to review the exposure of concern.",
"   </p>",
"   <p>",
"    Significant exposure to varicella infection, which is highly contagious, is defined as household contact, face to face contact with an index case for five minutes, or sharing the same hospital room with a contagious patient.",
"   </p>",
"   <p>",
"    Herpes zoster is much less contagious and usually requires close contact or exposure to open cutaneous lesions for transmission to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/4\">",
"     4",
"    </a>",
"    ], although rare cases of airborne transmission have been reported in nosocomial settings. Nonimmune women who have had such exposures to zoster infection should also be considered for postexposure prophylaxis since they are at risk for primary varicella infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=see_link\">",
"     \"Prevention and control of varicella in hospitals\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention and control of varicella in hospitals\", section on 'Transmission from persons with zoster'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234335\">",
"    <span class=\"h2\">",
"     Immunoprophylaxis for the prevention of maternal varicella infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Passive immunization with VZV-specific antibodies reduces the risk of varicella infection and also attenuates the severity of infection in those who seroconvert [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/54\">",
"     54",
"    </a>",
"    ]. The US Advisory Committee on Immunization Practices recommends VariZIG in all nonimmune pregnant women who have been exposed to persons with VZV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/23,56\">",
"     23,56",
"    </a>",
"    ]. Postexposure prophylaxis is not needed among women who were immunized with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in the past.",
"   </p>",
"   <p>",
"    Patients need careful follow-up for signs of infection despite passive immunization. Those who are infected despite postexposure prophylaxis should be treated for varicella infection. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Treatment of varicella infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260109\">",
"    <span class=\"h3\">",
"     Which product should be used?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, passive immunization was administered with zoster immune globulin (ZIG) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8326?source=see_link\">",
"     varicella zoster immune globulin",
"    </a>",
"    (VZIG), but these products are no longer available. VariZIG is the only formulation for passive immunization that is currently available in the United States. Data on the use of VariZIG during pregnancy are given below; further details on the efficacy of immunoprophylaxis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260146\">",
"    <span class=\"h4\">",
"     VariZIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;In February 2006, an investigational",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8326?source=see_link\">",
"     varicella zoster immune globulin",
"    </a>",
"    product, VariZIG (Cangene Corporation, Winnipeg, Canada) became available under an investigational new drug application submitted to the FDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/57\">",
"     57",
"    </a>",
"    ]. VariZIG is a purified human immune globulin preparation made from plasma containing high levels of anti-varicella antibodies. VariZIG undergoes filtration and inactivation to decrease the transmission of known viruses such as HIV and hepatitis viruses. &nbsp;",
"   </p>",
"   <p>",
"    In a study of 60 pregnant females who were randomly assigned to either VZIG or VariZIG administered after varicella exposure, the efficacy and safety of the two products were similar over the 28-day period of follow-up; 29 percent developed varicella in the VariZIG group compared with 42 percent in the VZIG arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/53\">",
"     53",
"    </a>",
"    ]. At 48 hours, patients who received VariZIG via the intravenous route had higher VZV antibody titers than those women who received either VZIG or VariZIG through the intramuscular route. These rates of infection are lower than historical controls (ie, &gt;90 percent).",
"   </p>",
"   <p>",
"    VariZIG should be administered as soon as possible within 10 days of exposure. Limited data suggest that the incidence of varicella is comparable among people who receive passive immunization within four days or within 5 to 10 days of varicella exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/53,58\">",
"     53,58",
"    </a>",
"    ]. The efficacy of passive immunization after this time interval is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/59\">",
"     59",
"    </a>",
"    ]. VariZIG is supplied as a lyophilized powder for reconstitution in 125-unit vials. The recommended dose is 125",
"    <span class=\"nowrap\">",
"     units/10",
"    </span>",
"    kg body weight given IM, with a maximum dose of 625 units (5 vials).",
"   </p>",
"   <p>",
"    FFF Enterprises is the sole authorized US distributor of VariZIG (24-hour telephone: 800-843-7477, Temecula, California). After a review of eligibility, it can be delivered, according to the distributor, within 24 hours of a request [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1098897\">",
"    <span class=\"h4\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant women who cannot receive VariZIG within 10 days of exposure, clinicians may choose either to administer a single dose of intravenous immunoglobulin (IVIG) at 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/23\">",
"     23",
"    </a>",
"    ] or closely monitor for signs and symptoms of varicella and institute treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    if illness occurs. IVIG is not routinely screened for antibodies against varicella virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260160\">",
"    <span class=\"h2\">",
"     Immunoprophylaxis for the prevention of congenital varicella syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the rarity of congenital varicella syndrome, there are no definitive data that immunoprophylaxis prevents embryopathy among women who develop varicella despite prophylaxis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort of 1739 women who had varicella or herpes zoster during gestation, 97 women had received VZIG to prevent varicella infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3\">",
"       3",
"      </a>",
"      ]. There were no cases of congenital varicella syndrome among the infants born to women who had received prophylaxis; however, the overall risk of congenital varicella syndrome was also low among infants born to women who did not receive prophylaxis (0.7 percent; 9 cases of 1373 women with varicella). No cases of congenital varicella syndrome were diagnosed among women with zoster.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary reason to offer immunoprophylaxis to all VZV-exposed pregnant females is to decrease the risk of maternal infection and maternal morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/60\">",
"     60",
"    </a>",
"    ]. Women who are protected from acquiring varicella are not at risk of having an infant with congenital varicella syndrome. Among women who do acquire VZV despite immunoprophylaxis, it is biologically plausible that passive immunization might decrease viremia, leading to a lower risk of mother-to-child transmission. (See",
"    <a class=\"local\" href=\"#H234335\">",
"     'Immunoprophylaxis for the prevention of maternal varicella infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3722830\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is beneficial in reducing the risk of varicella after exposure during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=see_link&amp;anchor=H16#H16\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\", section on 'Acyclovir for postexposure prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1098198\">",
"    <span class=\"h1\">",
"     PRE-EXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;VARIVAX, a live attenuated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , is recommended by the ACIP for susceptible children under age 13 years and susceptible young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. The estimated vaccine efficacy over a 10-year observation period of two doses for prevention of varicella is 98 percent with 100 percent efficacy for prevention of severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/19\">",
"     19",
"    </a>",
"    ]. The seroconversion rate after vaccination is approximately 82 percent in adults and 91 percent for children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71930708\">",
"    <span class=\"h2\">",
"     Nonpregnant females",
"    </span>",
"    &nbsp;&mdash;&nbsp;The negative effects of varicella infection on maternal, fetal and neonatal morbidity and mortality are preventable with varicella immunization prior to onset of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/26\">",
"     26",
"    </a>",
"    ]. The Advisory Committee on Immunization Practices recommends that all women of child-bearing age be assessed prenatally for evidence of varicella immunity by either [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/7,61\">",
"     7,61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of previous vaccination",
"     </li>",
"     <li>",
"      Prior varicella infection",
"     </li>",
"     <li>",
"      Laboratory evidence of immunity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonpregnant women who do not have evidence of immunity to varicella should be offered the standard dosing of vaccine (ie, 2 doses four to eight weeks apart) to prevent varicella-related morbidity and mortality. One analysis suggested that such a universal approach is more cost-effective than offering immunoprophylaxis to women during pregnancy for postexposure prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women should avoid becoming pregnant for one month after immunization because of theoretical concerns regarding risk to the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/17,61,63\">",
"     17,61,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71930723\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women should",
"    <strong>",
"     not",
"    </strong>",
"    receive this live vaccine because of the theoretical risk of inducing congenital disease. However, if a pregnant woman is found to be nonimmune during pregnancy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    should be recommended immediately after delivery with the second dose administered at the six-week postpartum visit.",
"   </p>",
"   <p>",
"    Immunizations during pregnancy and the breastfeeding period are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VARIVAX, a live attenuated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , is recommended for susceptible children under age 13 years and susceptible young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. The estimated vaccine efficacy over a 10-year observation period of two doses for prevention of varicella is 98 percent with 100 percent efficacy for prevention of severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33225/abstract/19\">",
"     19",
"    </a>",
"    ]. The seroconversion rate after vaccination is approximately 82 percent in adults and 91 percent for children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24973917\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles). Varicella is generally a mild, self-limited illness in healthy children, but can occasionally lead to serious morbidity during pregnancy. (See",
"      <a class=\"local\" href=\"#H234396\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of varicella is low among adults because most are immune to infection. Although the incidence of varicella is not increased in pregnant compared with nonpregnant adults, disease severity appears to be higher during pregnancy. (See",
"      <a class=\"local\" href=\"#H2091906\">",
"       'Maternal varicella'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among women who develop varicella infection during pregnancy, the risk of congenital varicella syndrome appears to be small (0.4 to 2 percent). (See",
"      <a class=\"local\" href=\"#H2091913\">",
"       'Congenital varicella'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Varicella is highly communicable, with secondary attack rates in susceptible household contacts approaching 90 percent in the prevaccination era. Patients are infectious from one to two days prior to this rash until lesions are crusted over. Mother-to-child transmission of VZV can occur in utero, perinatally, or postnatally. (See",
"      <a class=\"local\" href=\"#H2091920\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vesicular rash of varicella appears in successive crops over several days on the face, trunk and extremities. (See",
"      <a class=\"local\" href=\"#H2092264\">",
"       'Uncomplicated varicella'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One of the most common maternal clinical manifestations of complicated varicella infection in pregnancy is varicella pneumonia. The clinical course is unpredictable and may rapidly progress to hypoxia and respiratory failure with high rates of mortality in untreated infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features of maternal VZV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital varicella syndrome is characterized by cutaneous scars, intrauterine growth retardation, and neurological, ocular and limb abnormalities. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fetal effects of VZV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of maternal varicella infection is clinical, based on the characteristic vesicular rash. (See",
"      <a class=\"local\" href=\"#H1098780\">",
"       'Maternal varicella'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After maternal infection, the risk of congenital varicella syndrome can be estimated using polymerase chain reaction (PCR) testing of fetal blood or amniotic fluid for VZV DNA, in conjunction with ultrasonography for detection of structural fetal abnormalities. (See",
"      <a class=\"local\" href=\"#H1098827\">",
"       'Congenital varicella syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiviral therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      in nonpregnant adults improves skin healing and the duration of fever, if initiated within 24 hours of symptom onset. There are no data to suggest that acyclovir prevents the development of complicated infection. A large prospective registry of acyclovir-exposed pregnancies suggests that acyclovir is not teratogenic, although large controlled trials have not been performed. We suggest oral acyclovir for pregnant women with uncomplicated varicella (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management of maternal VZV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are no direct controlled trials in nonpregnant or pregnant adults, mortality rates secondary to varicella pneumonia appear significantly lower with treatment compared with untreated historical controls. We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      for all pregnant women with varicella pneumonia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Acyclovir should be administered intravenously at 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight hours in patients with complicated varicella infection. (See",
"      <a class=\"local\" href=\"#H259849\">",
"       'Varicella pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postexposure prophylaxis is targeted to susceptible pregnant women (eg, those without a history of varicella or those who are seronegative) who have had a significant exposure to a person with varicella or zoster. Since many women have serologic evidence of past infection, it appears cost-effective to serologically screen prior to prophylaxis, when feasible. However, immunoprophylaxis should not be delayed for more than 96 hours after exposure since efficacy beyond this time point is unknown. (See",
"      <a class=\"local\" href=\"#H3722805\">",
"       'Evaluating susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunoprophylaxis (eg, VariZIG) is associated with a lower risk of acquisition of varicella after exposure and milder illness in those who seroconvert despite postexposure prophylaxis. Persons who undergo immunoprophylaxis need careful follow-up for symptoms of varicella infection. (See",
"      <a class=\"local\" href=\"#H234335\">",
"       'Immunoprophylaxis for the prevention of maternal varicella infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend postexposure prophylaxis with an immunoglobulin product containing high titers of VZV-specific antibodies compared with watchful waiting (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In the United States, VariZIG is the only available product with VZV-specific antibodies. Administration of VariZIG should occur within 10 days of exposure. (See",
"      <a class=\"local\" href=\"#H260146\">",
"       'VariZIG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persons who undergo immunoprophylaxis need careful follow-up for symptoms of varicella infection. (See",
"      <a class=\"local\" href=\"#H234335\">",
"       'Immunoprophylaxis for the prevention of maternal varicella infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The negative effects of varicella infection on maternal, fetal and neonatal morbidity and mortality are preventable with varicella immunization prior to onset of pregnancy. The safety and efficacy of varicella vaccination is discussed in detail elsewhere. (See",
"      <a class=\"local\" href=\"#H1098198\">",
"       'Pre-exposure prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"       \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/1\">",
"      Lamont RF, Sobel JD, Carrington D, et al. Varicella-zoster virus (chickenpox) infection in pregnancy. BJOG 2011; 118:1155.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm (Accessed on July 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/3\">",
"      Enders G, Miller E, Cradock-Watson J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/4\">",
"      Cohen A, Moschopoulos P, Maschopoulos P, et al. Congenital varicella syndrome: the evidence for secondary prevention with varicella-zoster immune globulin. CMAJ 2011; 183:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/5\">",
"      Stagno S, Whitley RJ. Herpesvirus infections of pregnancy. Part II: Herpes simplex virus and varicella-zoster virus infections. N Engl J Med 1985; 313:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/6\">",
"      Gershon AA, Raker R, Steinberg S, et al. Antibody to Varicella-Zoster virus in parturient women and their offspring during the first year of life. Pediatrics 1976; 58:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/7\">",
"      Watson B, Civen R, Reynolds M, et al. Validity of self-reported varicella disease history in pregnant women attending prenatal clinics. Public Health Rep 2007; 122:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/8\">",
"      Plans P, Costa J, Espu&ntilde;es J, et al. Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women of childbearing age. BJOG 2007; 114:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/9\">",
"      Koren G. Congenital varicella syndrome in the third trimester. Lancet 2005; 366:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/10\">",
"      Alanen A, Kahala K, Vahlberg T, et al. Seroprevalence, incidence of prenatal infections and reliability of maternal history of varicella zoster virus, cytomegalovirus, herpes simplex virus and parvovirus B19 infection in South-Western Finland. BJOG 2005; 112:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/11\">",
"      Harger JH, Ernest JM, Thurnau GR, et al. Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. J Infect Dis 2002; 185:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/12\">",
"      Schutte TJ, Rogers LC, Copas PR. Varicella pneumonia complicating pregnancy: a report of seven cases. Infect Dis Obstet Gynecol 1996; 4:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/13\">",
"      Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994; 330:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/14\">",
"      Harger JH, Ernest JM, Thurnau GR, et al. Frequency of congenital varicella syndrome in a prospective cohort of 347 pregnant women. Obstet Gynecol 2002; 100:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/15\">",
"      Jones KL, Johnson KA, Chambers CD. Offspring of women infected with varicella during pregnancy: a prospective study. Teratology 1994; 49:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/16\">",
"      Tan MP, Koren G. Chickenpox in pregnancy: revisited. Reprod Toxicol 2006; 21:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/17\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/18\">",
"      Higa K, Dan K, Manabe H. Varicella-zoster virus infections during pregnancy: hypothesis concerning the mechanisms of congenital malformations. Obstet Gynecol 1987; 69:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/19\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics 2007; 120:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/20\">",
"      Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 2008; 197 Suppl 2:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/21\">",
"      Khandaker G, Marshall H, Peadon E, et al. Congenital and neonatal varicella: impact of the national varicella vaccination programme in Australia. Arch Dis Child 2011; 96:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/22\">",
"      Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007; 356:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/23\">",
"      VariZIG for prophylaxis after exposure to varicella. Med Lett Drugs Ther 2006; 48:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/24\">",
"      Enright AM, Prober CG. Herpesviridae infections in newborns: varicella zoster virus, herpes simplex virus, and cytomegalovirus. Pediatr Clin North Am 2004; 51:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/25\">",
"      Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 1986; 314:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/26\">",
"      Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002; 186 Suppl 1:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/27\">",
"      Martin KA, Junker AK, Thomas EE, et al. Occurrence of chickenpox during pregnancy in women seropositive for varicella-zoster virus. J Infect Dis 1994; 170:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/28\">",
"      Suga S, Yoshikawa T, Ozaki T, Asano Y. Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Arch Dis Child 1993; 69:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/29\">",
"      Nikkels AF, Delbecque K, Pierard GE, et al. Distribution of varicella-zoster virus DNA and gene products in tissues of a first-trimester varicella-infected fetus. J Infect Dis 2005; 191:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/30\">",
"      Straus SE, Ostrove JM, Inchausp&eacute; G, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/31\">",
"      Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/32\">",
"      Pahud BA, Glaser CA, Dekker CL, et al. Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis 2011; 203:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/33\">",
"      Smego RA Jr, Asperilla MO. Use of acyclovir for varicella pneumonia during pregnancy. Obstet Gynecol 1991; 78:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/34\">",
"      LAFORET EG, LYNCH CL Jr. Multiple congenital defects following maternal varicella; report of a case. N Engl J Med 1947; 236:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/35\">",
"      Mazzella M, Arioni C, Bellini C, et al. Severe hydrocephalus associated with congenital varicella syndrome. CMAJ 2003; 168:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/36\">",
"      Mouly F, Mirlesse V, M&eacute;ritet JF, et al. Prenatal diagnosis of fetal varicella-zoster virus infection with polymerase chain reaction of amniotic fluid in 107 cases. Am J Obstet Gynecol 1997; 177:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/37\">",
"      Siegel M. Congenital malformations following chickenpox, measles, mumps, and hepatitis. Results of a cohort study. JAMA 1973; 226:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/38\">",
"      Siegel M, Fuerst HT, Peress NS. Comparative fetal mortality in maternal virus diseases. A prospective study on rubella, measles, mumps, chicken pox and hepatitis. N Engl J Med 1966; 274:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/39\">",
"      Balducci J, Rodis JF, Rosengren S, et al. Pregnancy outcome following first-trimester varicella infection. Obstet Gynecol 1992; 79:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/40\">",
"      Cuthbertson G, Weiner CP, Giller RH, Grose C. Prenatal diagnosis of second-trimester congenital varicella syndrome by virus-specific immunoglobulin M. J Pediatr 1987; 111:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/41\">",
"      Isada NB, Paar DP, Johnson MP, et al. In utero diagnosis of congenital varicella zoster virus infection by chorionic villus sampling and polymerase chain reaction. Am J Obstet Gynecol 1991; 165:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/42\">",
"      Essex-Cater A, Heggarty H. Fatal congenital varicella syndrome. J Infect 1983; 7:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/43\">",
"      Alkalay AL, Pomerance JJ, Rimoin DL. Fetal varicella syndrome. J Pediatr 1987; 111:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/44\">",
"      Wallace MR, Bowler WA, Murray NB, et al. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/45\">",
"      Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol 2004; 70:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/46\">",
"      Pickard RE. Varicella pneumonia in pregnancy. Am J Obstet Gynecol 1968; 101:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/47\">",
"      Broussard RC, Payne DK, George RB. Treatment with acyclovir of varicella pneumonia in pregnancy. Chest 1991; 99:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/48\">",
"      Cox SM, Cunningham FG, Luby J. Management of varicella pneumonia complicating pregnancy. Am J Perinatol 1990; 7:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/49\">",
"      Al-Nakib W, Al-Kandari S, El-Khalik DM, El-Shirbiny AM. A randomised controlled study of intravenous acyclovir (Zovirax) against placebo in adults with chickenpox. J Infect 1983; 6:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/50\">",
"      Reiff-Eldridge R, Heffner CR, Ephross SA, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/51\">",
"      Pacifici GM. Transfer of antivirals across the human placenta. Early Hum Dev 2005; 81:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/52\">",
"      McGregor JA, Mark S, Crawford GP, Levin MJ. Varicella zoster antibody testing in the care of pregnant women exposed to varicella. Am J Obstet Gynecol 1987; 157:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/53\">",
"      Koren G, Money D, Boucher M, et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. J Clin Pharmacol 2002; 42:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/54\">",
"      Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin. A further assessment. N Engl J Med 1974; 290:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/55\">",
"      Rouse DJ, Gardner M, Allen SJ, Goldenberg RL. Management of the presumed susceptible varicella (chickenpox)-exposed gravida: a cost-effectiveness/cost-benefit analysis. Obstet Gynecol 1996; 87:932.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/57\">",
"      Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/58\">",
"      Evans EB, Pollock TM, Cradock-Watson JE, Ridehalgh MK. Human anti-chickenpox immunoglobulin in the prevention of chickenpox. Lancet 1980; 1:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/59\">",
"      Centers for Disease Control and Prevention (CDC). FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 2012; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/60\">",
"      Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/61\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/62\">",
"      Troughton JA, Crealey G, Crawford V, Coyle PV. Management of varicella contacts in pregnancy: VZIG or vaccination? J Clin Virol 2009; 46:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33225/abstract/63\">",
"      Coonrod DV, Jack BW, Boggess KA, et al. The clinical content of preconception care: immunizations as part of preconception care. Am J Obstet Gynecol 2008; 199:S290.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8331 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33225=[""].join("\n");
var outline_f32_28_33225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24973917\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234396\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2091972\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2092079\">",
"      Varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2092072\">",
"      Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24973924\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2091906\">",
"      Maternal varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2091913\">",
"      Congenital varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234536\">",
"      Effect of varicella vaccine on VZV epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2091920\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2091946\">",
"      Person to person",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2091964\">",
"      Mother to infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2092125\">",
"      INCUBATION PERIOD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2092086\">",
"      Maternal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      In utero infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES OF MATERNAL VZV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2092264\">",
"      Uncomplicated varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2092271\">",
"      Complicated infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Varicella pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FETAL EFFECTS OF VZV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical features of congenital varicella syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1098652\">",
"      Prematurity and spontaneous abortion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neonatal VZV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1098780\">",
"      Maternal varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1098827\">",
"      Congenital varicella syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2130642\">",
"      - Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2130764\">",
"      - Postnatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT OF MATERNAL VZV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment of varicella infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259842\">",
"      - Uncomplicated varicella infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H259849\">",
"      - Varicella pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment of herpes zoster infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24974620\">",
"      POST-EXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3722805\">",
"      Evaluating susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260293\">",
"      Defining exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234335\">",
"      Immunoprophylaxis for the prevention of maternal varicella infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H260109\">",
"      - Which product should be used?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H260146\">",
"      VariZIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1098897\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260160\">",
"      Immunoprophylaxis for the prevention of congenital varicella syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3722830\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1098198\">",
"      PRE-EXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71930708\">",
"      Nonpregnant females",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71930723\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24973917\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8331\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8331|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/3/36927\" title=\"picture 1\">",
"      Rash of primary varicella",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/77?source=related_link\">",
"      Diagnosis of varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32200?source=related_link\">",
"      Prevention and control of varicella in hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=related_link\">",
"      Varicella-zoster infection in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_28_33226="Psychogenic nonepileptic seizures";
var content_f32_28_33226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychogenic nonepileptic seizures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33226/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33226/contributors\">",
"     Alan B Ettinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33226/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33226/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/28/33226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/28/33226/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/28/33226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians are regularly challenged to identify the nature of episodic neurologic symptoms. Events associated with prominent motor activity or altered consciousness are often presumed to be epileptic seizures. However, the event may actually represent one of a wide array of nonepileptic paroxysmal events, such as syncope, parasomnias, and movement disorders.",
"   </p>",
"   <p>",
"    Another notable type of episodic behavior is a psychogenic nonepileptic seizure (PNES). Characterized by sudden and time-limited disturbances of motor, sensory, autonomic, cognitive,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emotional functions, PNES can mimic epileptic seizures. However, in contrast to epileptic seizures, PNES are not associated with physiological central nervous system dysfunction but are instead psychogenically determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other terms, such as pseudoseizures or hysterical seizures, have been used to describe these episodes. The term \"hysterical\" seizures or \"hysteroepilepsy\" is now discouraged as both pejorative and oversimplified, failing to capture the broad range of underlying psychopathology. The term \"pseudoseizures\" is also discouraged, since the root \"pseudo,\" or false, invalidates the genuine, even if psychogenic, disorder that a patient experiences.",
"   </p>",
"   <p>",
"    It is important that clinicians consider PNES when evaluating patients with episodic symptoms. Missing this diagnosis may result in inappropriate treatment with antiepileptic drugs that are associated with potential morbidity, especially if drug toxicity is incurred in the attempt to suppress episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Prolonged episodes, \"psychogenic status epilepticus\" in particular, are often treated with toxic antiepileptic drug doses, intubation, and iatrogenically induced coma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/6-14\">",
"     6-14",
"    </a>",
"    ]. When PNES occur during pregnancy, these treatments pose additional risks to the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/2\">",
"     2",
"    </a>",
"    ]. Recurrent visits to the emergency room and hospitalizations for uncontrolled, unrecognized PNES place a cost burden on the healthcare system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/15\">",
"     15",
"    </a>",
"    ]. Finally, failure to recognize psychiatric issues may promote the persistence of conversion symptoms and deny the patient needed psychiatric interventions.",
"   </p>",
"   <p>",
"    The diagnosis of PNES can be challenging. In some case series, delay to PNES diagnosis has been as long as 9 to 16 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This is due in part to the broad diversity of PNES presentations and the lack of one single unifying presenting symptom. Other sources of misdiagnosis include an inadequate history, co-occurrence of PNES and epilepsy in the same patient, poor physician-patient rapport, reliance upon clinical observation of the event, discomfort in making a psychiatric diagnosis, and reluctance to obtain a psychiatric evaluation before the clinician feels confident about the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/18\">",
"     18",
"    </a>",
"    ]. While advances in technology, especially the advent of video-electroencephalography, have greatly advanced our ability to recognize PNES, an accurate diagnosis is best achieved by assimilating a wide variety of clues including a detailed history from the patient and observers, the physical examination, selected testing, and a psychiatric evaluation.",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, diagnosis, and treatment of PNES are discussed here. Other nonepileptic paroxysmal disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incidence rates of PNES in the general population are not well established. One epidemiologic study in Iceland reported an incidence rate of 1.4 per 100,000 individuals over age 15 years; a study in Ohio documented a mean incidence of 3 per 100,000 between 1995 and 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/3,5,19\">",
"     3,5,19",
"    </a>",
"    ]. The prevalence of PNES has been estimated to be between 2 to 33 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients referred to outpatient epilepsy centers, 5 to 25 percent of patients are felt to have PNES, while 25 to 40 percent of patients evaluated in inpatient epilepsy monitoring units for intractable seizures are diagnosed with PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/3,21\">",
"     3,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PNES most commonly presents in the third decade of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/17,22-25\">",
"     17,22-25",
"    </a>",
"    ]. However, most age groups can be affected, including young children and the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. One study suggests that the age of onset may be influenced by pre-existing conditions; patients with learning disabilities had a relatively younger age of onset compared to those with a history of physical or psychosocial trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29175?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=see_link\">",
"     \"Treatment of seizures and epilepsy in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PNES has a female predominance ranging from 66 to 99 percent in different series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/5,22,23,25,28,31-35\">",
"     5,22,23,25,28,31-35",
"    </a>",
"    ]. This is consistent with gender ratios described in conversion disorder, one of the salient psychiatric conditions underlying PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Psychosocial history'",
"    </a>",
"    below.) Race, marital status, and years of education do not appear to influence the prevalence of PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognizing PNES can be challenging even for experienced observers, in part because of the broad diversity of presentations. Nonetheless, clues that arouse suspicion for this diagnosis are often apparent from the clinical history (",
"    <a class=\"graphic graphic_table graphicRef77773 \" href=\"mobipreview.htm?5/53/5980\">",
"     table 1",
"    </a>",
"    ). One systematic review found that long duration, occurrence from sleep, fluctuating course, asynchronous movements, pelvic thrusting, side-to-side head or body movements, ictal eye closing, ictal crying, memory recall, and absent postictal confusion were the most reliable signs in distinguishing PNES from epileptic seizure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/38\">",
"     38",
"    </a>",
"    ]. It is important to remember that no single feature is either sensitive or specific for PNES.",
"   </p>",
"   <p>",
"    A history from patients with suspected PNES should elicit information relevant to any paroxysmal disorder including seizures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Detailed description of the event as perceived by the patient and as witnessed by others, including prodromal and postictal features",
"     </li>",
"     <li>",
"      Precipitants, circumstances in which episodes occur",
"     </li>",
"     <li>",
"      Episode frequency, duration",
"     </li>",
"     <li>",
"      Factors that reduce seizure frequency or attenuate an episode",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is important to note that patients as well as eyewitnesses can report clinical features that are discrepant from each other and from review of video recorded events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Precipitants and setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The setting in which an episode occurs can be helpful in distinguishing PNES and epilepsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most episodes of PNES occur in front of witnesses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/29,41,42\">",
"       29,41,42",
"      </a>",
"      ]. In one study, the occurrence of an episode in the doctor's waiting or examination room was estimated to have a 75 percent predictive value for PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/41\">",
"       41",
"      </a>",
"      ]. Similarly, in a study of patients undergoing EEG monitoring, episodes that occurred at the time of electrode placement were found to be PNES, not epileptic seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PNES tend not to occur during sleep [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/38,43\">",
"       38,43",
"      </a>",
"      ]. In contrast, epileptic seizures can occur during sleep, and in some forms of epilepsy, nocturnal episodes are most frequent. However, nocturnal seizures are frequently unwitnessed, and patients with PNES may report (erroneously) that seizures occur during sleep [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. Patients with PNES may appear to be asleep just before seizure-onset, but the EEG in these cases demonstrates wakefulness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Video-EEG monitoring'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      While it is intuitive that PNES would be more likely to be associated with stressful situations, stress is also commonly cited as a seizure precipitant in patients with epilepsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. In one series of patients with PNES, witness responders were more likely than patients to associate emotional stress as a trigger for events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased seizure frequency during the perimenstrual time period suggests epileptic seizures. In one series, perimenstrual exacerbation was associated with 13 of 27 patients with epileptic seizures versus 1 of 38 patients with PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PNES are often frequent. At the time of evaluation, most patients report at least daily episodes; whereas less than one event a week is uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/5,17,23,25,35,42,50\">",
"       5,17,23,25,35,42,50",
"      </a>",
"      ]. This observation may reflect a sampling bias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ictal features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unresponsive behavior with motor manifestations mimicking a generalized convulsion or a complex partial seizure is the most common manifestation of a PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/22,23,28,33,42,50-52\">",
"     22,23,28,33,42,50-52",
"    </a>",
"    ]. Less common are events that mimic atonic, absence, or simple partial seizures. A variety of clinical behaviors may occur during PNES, some of which are useful in distinguishing them from epileptic seizures (",
"    <a class=\"graphic graphic_table graphicRef77773 \" href=\"mobipreview.htm?5/53/5980\">",
"     table 1",
"    </a>",
"    ). However, no single semiologic feature is either sensitive or specific for PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, eyewitness reports by family members and caregivers can be unreliable in their description of these features, when compared to video review of events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of convulsive-like motor activity can occur in PNES. While motor manifestations of an epileptic seizure usually take the form of brief tonic posturing or a synchronized convulsion with a defined progression of motor activity; movements in PNES are more often asynchronous, variable, and wax and wane over the course of the ictus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/21,22,38,53\">",
"       21,22,38,53",
"      </a>",
"      ]. Specific movements such as writhing, thrashing, pelvic thrusts, opisthotonus (arched back), and jactitation (rolling from side to side) suggest PNES, but these are not always present, particularly in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/22,29,42,51,53,54\">",
"       22,29,42,51,53,54",
"      </a>",
"      ]. Moreover, some epileptic seizures, such as those of frontal lobe origin, can produce unusual-appearing motor activities similar to those seen in PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/21,38,44,55-60\">",
"       21,38,44,55-60",
"      </a>",
"      ]. Stereotyped and consistent lateralization of motor features usually, but not always, suggests epilepsy; some patients have PNES with consistent semiology and little variation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/38,44,52,61\">",
"       38,44,52,61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=see_link&amp;anchor=H12#H12\">",
"       \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Frontal lobe epilepsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Classic symptoms of epileptic seizures such as tongue biting, incontinence, and self-injury, are more common in epileptic seizures, but they can occur in a third or more of patients with PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/16,17,22,23,35,38,50,62\">",
"       16,17,22,23,35,38,50,62",
"      </a>",
"      ]. A tongue bitten on the side is more specific for epileptic seizure, than when bitten on the tip [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Incomplete loss of consciousness during the episode, suggested either by responsiveness to stimuli or by later recall of events during the ictus, suggests PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/22,39,64\">",
"       22,39,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Weeping, ictal stuttering, and vocalizations are relatively uncommon in epileptic seizures and suggest PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/29,38,65-68\">",
"       29,38,65-68",
"      </a>",
"      ]. When vocalization occurs in an epileptic seizure, it usually occurs at seizure onset, not during the convulsion, and is characterized by a fragmented guttural utterance, caused by a tonic diaphragm forcing air against tonic or clonic vocal cords [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A seizure aura is frequently reported in PNES (25 to 60 percent) and may be a more common symptom than in epilepsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/33,35,42\">",
"       33,35,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autonomic manifestations during an ictus (eg, tachycardia, cyanosis) suggest epileptic seizure, and their absence, particularly during a major convulsion, suggests PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/53,68,70\">",
"       53,68,70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Eyes are usually open during the ictus of a generalized convulsive seizure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/38,39,54,63,71\">",
"       38,39,54,63,71",
"      </a>",
"      ]. Forced eye closure in particular suggests PNES. Sensitivity and specificity of eye closure as a sign for PNES varies according to how it is defined [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/53\">",
"       53",
"      </a>",
"      ]. One study that calculated duration of time for eye closure (rather than absolute presence or absence) found only moderate sensitivity, but high specificity for PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/72\">",
"       72",
"      </a>",
"      ]. &nbsp;Similarly, in another study, eye opening at seizure onset was found to have a high sensitivity and lower specificity for epileptic seizure as compared to PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/39\">",
"       39",
"      </a>",
"      ]. In both of these series, observer reports of ictal eye closure were not reliable.",
"     </li>",
"     <li>",
"      Ictal atonia is not a common PNES manifestation, however, when prolonged, this almost always represents PNES, not epileptic seizure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While the ictus of an epileptic seizure is typically very brief, often less than one minute, PNES are rarely less than one minute and are usually much longer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/22-24,29,38,44,52,54,59,73,74\">",
"       22-24,29,38,44,52,54,59,73,74",
"      </a>",
"      ]. Prolonged episodes (ie, psychogenic status epilepticus) are not rare. In one series, 78 percent of patients with PNES reported at least one event longer the 30 minutes, and half of these patients had recurrent episodes of psychogenic status epilepticus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While stereotyped behaviors during events usually suggest seizures rather than PNES, one investigation that evaluated symptom clustering found that 61 percent of patients with PNES tended to have similar types of behavior during their attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Postictal symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid alerting and reorientation is common after PNES but uncommon with epileptic seizures, except for certain seizure types, such as absence or frontal lobe seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/38,39,42,44,55\">",
"       38,39,42,44,55",
"      </a>",
"      ]. However, in some case series, half or more of patients with PNES exhibited postictal confusion or drowsiness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/33,42\">",
"       33,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postictal headache occurs in up to half of patients with epileptic seizures, but is rare in PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The postictal period after a generalized tonic-clonic seizure was found in one cohort to be characterized by a breathing pattern of deep and prolonged inspiratory and expiratory phases, compared with shallow, rapid respirations in patients after a PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/38,54,71\">",
"       38,54,71",
"      </a>",
"      ]. Epileptic seizures arising from the frontal lobe, however, were associated with a postictal breathing pattern similar to PNES. Another case series described a stertorous postictal breathing pattern after 6 of 27 epileptic seizures but in none of the 15 observed PNES [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postictal nose-wiping or coughing is a rare but somewhat specific feature of mesial temporal lobe seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PNES have seizures for many years prior to diagnosis, and most are treated unsuccessfully with antiepileptic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/5,16,23,28,33,42,51\">",
"     5,16,23,28,33,42,51",
"    </a>",
"    ]. A failure to make even small improvements in seizure frequency despite vigorous antiepileptic drug trials suggests the diagnosis of PNES.",
"   </p>",
"   <p>",
"    Similarly, patients who present with prolonged PNES are often treated with drug protocols for status epilepticus and fail to respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/7,10,13\">",
"     7,10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ASSOCIATED FEATURES AND CONDITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Psychosocial history",
"    </span>",
"    &nbsp;&mdash;&nbsp;While patients with PNES have a higher burden of psychiatric disease and symptoms than control groups with epilepsy, these conditions are also common in patients with epilepsy and are not specific for PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/17,22,24,25,35,73,77-80\">",
"     17,22,24,25,35,73,77-80",
"    </a>",
"    ]. The presence of these conditions is often not known at the time of presentation with PNES and may instead be revealed later as part of the evaluation when sufficient rapport has been established.",
"   </p>",
"   <p>",
"    Psychiatric conditions associated with PNES include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/33,35,50,78,79,81-87\">",
"     33,35,50,78,79,81-87",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Anxiety",
"     </li>",
"     <li>",
"      Somatoform disorder",
"     </li>",
"     <li>",
"      Posttraumatic stress disorder",
"     </li>",
"     <li>",
"      Dissociative disorder",
"     </li>",
"     <li>",
"      Personality disorders, especially borderline personality disorder, but also narcissistic, histrionic, and antisocial personalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A history of sexual or physical abuse is also prevalent in patients with PNES; in various cohorts, this is reported in one-third to one-half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/17,30,33-35,77,88,89\">",
"     17,30,33-35,77,88,89",
"    </a>",
"    ]. However, in one case series, a past history of sexual abuse was equally prevalent (38 percent) among 37 patients with PNES and 58 patients with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/90\">",
"     90",
"    </a>",
"    ]. Patients with PNES who report a history of sexual abuse may be more likely to have events that are clinically more severe and more likely to resemble epileptic seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/91\">",
"     91",
"    </a>",
"    ]. In another series they were also more likely to exhibit self-harming behaviors and other medically unexplained symptoms in addition to PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dysfunctional family relationships (poor communication or support, interpersonal conflict, trauma) are also reported by many PNES patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/33,92-94\">",
"     33,92-94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, depression with major psychosis and schizophrenia are relatively uncommon in patients with PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors distinguish between comorbid and etiologic psychiatric conditions, but this implies a detailed understanding of the pathophysiology of these symptoms, which is lacking. These disorders overlap, and it is common for patients to have more than one of these conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/78\">",
"     78",
"    </a>",
"    ]. As an example, dissociation is often associated with posttraumatic stress disorder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of physical or sexual abuse.",
"   </p>",
"   <p>",
"    Dissociative disorders and",
"    <span class=\"nowrap\">",
"     somatoform/conversion",
"    </span>",
"    disorders are felt to underlie most PNES, but this remains unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/95\">",
"     95",
"    </a>",
"    ]. In these conditions, physical symptoms occur in response to psychosocial stress, and are not intentionally produced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/35,84\">",
"     35,84",
"    </a>",
"    ]. This contrasts with factitious disorder or malingering, in which symptoms are, at least to some extent, voluntary and consciously produced. Factitious disorders and malingering are rarely responsible for PNES. While the clinician should seek evidence for potential primary gain (affording relief from emotional conflict or tension) and secondary gain (deriving advantages such as attention, relief from responsibilities, or attaining disability benefits), it should never be assumed that patients with PNES are \"faking\" their symptoms.",
"   </p>",
"   <p>",
"    Psychosocial stressors that may precipitate the emergence of PNES in vulnerable patients include bereavement; unwanted pregnancy; ongoing physical, verbal, or sexual abuse; lawsuits; job pressure; financial difficulties; impending divorce; domestic conflicts; and assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/2,17,33,35,81\">",
"     2,17,33,35,81",
"    </a>",
"    ]. In children, separation anxiety, school avoidance, and parental discord or divorce may also play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/26,96\">",
"     26,96",
"    </a>",
"    ]. Sometimes the recent event seems relatively minor, but may serve as the \"last straw\" in a series of events or may serve as a reminder of more significant remote events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Concurrent or past epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the prevalence of concurrent epilepsy among patients with PNES vary from 5 to 56 percent, in part because of differing diagnostic criteria used to determine the coexistence of epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/28,30,33,35,98-102\">",
"     28,30,33,35,98-102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case series with video-EEG documentation of both PNES and epileptic seizures in the same patient, there was notably different clinical semiology for PNES compared to epileptic seizures in 18 of 20 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/103\">",
"     103",
"    </a>",
"    ]. However, another series found that patients with PNES and probable temporal lobe epilepsy had symptoms that appeared to be more characteristic of temporal lobe seizures, possibly because of learned behaviors from their own seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few patients (2 to 9 percent) with epilepsy develop PNES after epilepsy surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. These typically emerge within the first several months, at a time when other psychiatric complications are also most incident. These patients often manifest other symptoms of psychiatric distress (eg, anxiety, psychosis). The symptoms may approximate presurgical epileptic events but are often very different. This phenomenon may be due in part to a paradoxical dependence on seizures and all of its psychosocial ramifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Seizure model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PNES have often witnessed epileptic events that may serve as a clinical model. A seizure history in a friend or relative, or an occupation as a healthcare worker is not uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/33\">",
"     33",
"    </a>",
"    ]. In one study, patients with PNES were significantly more likely to have witnessed an epileptic seizure prior to their event than were patients with epilepsy (66 versus 11 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/108\">",
"     108",
"    </a>",
"    ]. Alternatively, a patient's own history of epilepsy may be the model for their PNES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Comorbid neurologic and medical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;While underlying neurologic disease is more prevalent among patients with epilepsy than PNES, a history of neurologic insults, particularly minor head trauma, is common (30 to 44 percent) in PNES patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/28,35,77,102,109-111\">",
"     28,35,77,102,109-111",
"    </a>",
"    ]. It is not clear why such an association should exist. The head injury may be associated with psychological as well as physical trauma, which may serve as a precipitant for PNES. In some series, a patient's disability status or litigation for damages appeared to provide a source of secondary gain for PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/77\">",
"     77",
"    </a>",
"    ]. Recall bias may also contribute to this apparent association.",
"   </p>",
"   <p>",
"    PNES is also well-described in patients with neurologic developmental disabilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/28,112,113\">",
"     28,112,113",
"    </a>",
"    ]. In this population, distinguishing these events from epileptic seizures and other repetitive, stereotyped behaviors is a particular challenge. In one study, individuals with PNES and learning disabilities were more likely to have circumstantial triggering of events and more prolonged events than individuals without learning disabilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A history of recurrent medical evaluations for other unexplained somatic complaints should be examined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/78\">",
"     78",
"    </a>",
"    ]. As examples, a history of chronic pain or fibromyalgia is common among patients with PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/41,48,111\">",
"     41,48,111",
"    </a>",
"    ]. In one series, 30 percent of PNES patients had a sufficient burden of gastrointestinal complaints, pain, fatigue, and other complaints to meet criteria for an undifferentiated somatoform disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Examination findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination of patients with PNES may be completely normal, demonstrate neurologic abnormalities associated with unrelated neurologic disorders, or exhibit classic signs of conversion disorder. In the latter circumstance, the clinician may find a variety of abnormalities that do not make physiologic sense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A classic sign of conversion disorder is an apparent lack of concern for serious clinical symptoms (so-called \"belle indifference\"). However, some believe this finding is overemphasized in PNES patients and may be absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary consideration in the differential diagnosis of PNES are epileptic seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/99\">",
"     99",
"    </a>",
"    ]. Seizures arising from the frontal lobe in particular are often mistaken for PNES because of their unusual semiology. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Ictal features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinical features that suggest frontal lobe seizures rather than PNES are a brief duration (less than one minute), stereotyped manifestations, eyes-open during the ictus, and their occurrence during physiologic sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/44,59,71\">",
"     44,59,71",
"    </a>",
"    ]. In one video-EEG study, tonic contraction of the upper extremities in abduction was a feature of 90 percent of 63 supplementary motor seizures and occurred in none of 111 PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=see_link&amp;anchor=H12#H12\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Frontal lobe epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other nonepileptic paroxysmal disorders may be mistaken for either epileptic seizures or for PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/99\">",
"     99",
"    </a>",
"    ]. These include sleep disorders, movement disorders, and syncope (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"mobipreview.htm?31/38/32364\">",
"     table 2",
"    </a>",
"    ). These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, clinical features of events are often not sufficiently sensitive or specific to definitively distinguish seizures from PNES; as a result, confirmatory testing is usually required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/115\">",
"     115",
"    </a>",
"    ]. While not without limitations, video-electroencephalography (EEG) is the gold standard test for the diagnosis of PNES and should be performed in all patients in whom this diagnosis is suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/24,116\">",
"     24,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PNES are also likely to undergo other diagnostic testing during the course of their evaluation. Some tests can provide support for the diagnosis, others may provide misleading information. Other tests, while not helpful in diagnosis of PNES, are potentially useful in evaluating comorbidities and choosing subsequent treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Routine EEG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine EEG is often inadequate for distinguishing epileptic seizures from PNES. One reason is that a routine EEG records activity for only 20 to 30 minutes and is therefore unlikely to capture an ictus. A normal interictal EEG does not exclude the possibility of epilepsy or confirm the diagnosis of PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/117\">",
"     117",
"    </a>",
"    ]. At the same time, interictal epileptiform abnormalities do not rule out PNES. While more prevalent among patients with epilepsy, these are also seen in patients with PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/16,103,118\">",
"     16,103,118",
"    </a>",
"    ]. In patients felt to have PNES alone (no comorbid epilepsy), the prevalence of interictal EEG abnormalities ranges from 10 to 18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/16,23,101,102,110,118\">",
"     16,23,101,102,110,118",
"    </a>",
"    ]. An abnormal interictal EEG is more common if there is a past or concurrent history of epilepsy or other underlying neurologic injury or disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Video-EEG monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-EEG monitoring combines extended EEG monitoring with time-locked video acquisition that allows for analysis of clinical and electrographic features during a captured event. The yield of monitoring is high; 73 to 96 percent of patients will have typical PNES within first 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/24,43,119,120\">",
"     24,43,119,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caution is required for interpretation. While the majority of generalized tonic-clonic seizures reveal an ictal EEG correlate, the tracing may be obscured by muscle artifact. On the other hand, only 15 to 33 percent of simple partial seizures or seizure auras, which involve a limited brain area and are of deep origin, are associated with surface EEG abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/121\">",
"     121",
"    </a>",
"    ]. Furthermore, in some seizures, the early onset of motor activity results in artifacts that can obscure EEG changes. As a result, failure to see an electrographic seizure does not exclude epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accurate interpretation of video-EEG monitoring requires careful analysis of the clinical events with any changes in the EEG occurring before, during, and after the seizure. As one example, a finding of \"preictal pseudosleep\", the appearance of clinical sleep while the EEG tracing demonstrates wakefulness is a very specific, although insensitive, indicator of PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with diverse episode types may have both epileptic seizures and PNES. It is important to determine from both patients and family members that the event captured on video-EEG is typical of the events that are being evaluated. It can be helpful to show the video of the event to family members who can indicate how closely it resembles prior events they have witnessed.",
"   </p>",
"   <p>",
"    One study of interrater reliability of video-EEG found only moderate agreement (kappa = 0.57) for the diagnosis of PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/122\">",
"     122",
"    </a>",
"    ]. Limitations of this study that differ from \"real-life\" use of this test include a forced choice paradigm (epileptic versus psychogenic nonepileptic versus physiologic nonepileptic seizures) that was based on the analysis of a single episode with no access to other clinical data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Spell induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-EEG monitoring may be supplemented with the administration of a placebo designed to induce a PNES. This may be helpful if the patient fails to have a spontaneous event during prolonged video-EEG monitoring.",
"   </p>",
"   <p>",
"    This maneuver is typically performed by administering intravenous saline or rubbing alcohol on the skin of the patient and telling the patient that this may induce an episode. Between 67 to 90 percent of patients with PNES will have a typical event in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/2,5,42,123-126\">",
"     2,5,42,123-126",
"    </a>",
"    ]. While much less common, epileptic events have also been reported to occur with induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/99,101,119,127-129\">",
"     99,101,119,127-129",
"    </a>",
"    ]. Because of this, induction should be performed during video-EEG. It is also essential to confirm that the elicited episode is representative of the spells under investigation. A patient with epilepsy may have a PNES under these circumstances, but the features are usually atypical of their usual events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of this technique is controversial. While facilitating diagnosis, the inherent deceit in this approach may jeopardize the physician-patient relationship and impede future treatment efforts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/131\">",
"     131",
"    </a>",
"    ]. However, some experts believe that these considerations are outweighed by the benefits of making an accurate diagnosis and avoiding future morbidity associated with inappropriate treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/5,132,133\">",
"     5,132,133",
"    </a>",
"    ]. Alternative techniques that employ photic stimulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperventilation with suggestion may obviate the deceitful aspects, as these are routinely used to precipitate epileptic seizures. This approach may be more acceptable to patients and physicians, although special care is required as an epileptic seizure is more likely to be precipitated with these techniques, than with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/42,123\">",
"     42,123",
"    </a>",
"    ]. As an alternative, some physicians report that they successfully use placebo induction techniques after informing the patient that they are being used to elicit a possible psychogenic as well as epileptic seizure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/134\">",
"     134",
"    </a>",
"    ]. This transparency avoids deceit and makes this technique ethically more acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other monitoring techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sometimes, in spite of prolonged video-EEG and use of induction techniques, no episode is recorded. In such cases, outpatient ambulatory EEG, ideally with concomitant video may be helpful. Advising family members to have a video camera ready to record on stand-by can be helpful as well. While the absence of concomitant EEG is a significant limitation, direct observation of the clinical event can provide the physician with valuable information that aids in the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Ictal features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Serum testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain laboratory studies can help differentiate PNES from epileptic seizure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolactin levels are often elevated after an epileptic seizure, depending on the seizure type [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. Pooled sensitivity from several studies report prolactin level elevations (twice the baseline level) in 60 percent of generalized tonic clonic seizures and 46 percent of complex partial seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/135\">",
"       135",
"      </a>",
"      ]. The sensitivity is lower for simple partial seizures. Prolactin levels are less likely to rise after seizures that do not involve mesial temporal areas, making this a less sensitive test for epileptic seizures arising from the frontal lobe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/136\">",
"       136",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The timing of measuring prolactin is crucial. In typical cases, prolactin levels peak 15 to 20 minutes after the seizure and return to baseline levels within an hour [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/135\">",
"       135",
"      </a>",
"      ]. A baseline prolactin level should be determined from a blood sample drawn six hours after the event. Prolactin elevations have not been well characterized in the setting of repeated seizures or status epilepticus, and have unclear utility in this setting.",
"      <br/>",
"      <br/>",
"      Prolactin levels are unlikely to rise after a PNES, but elevations can occur after syncope [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/135,137\">",
"       135,137",
"      </a>",
"      ]. Dopamine antagonists (eg, neuroleptic agents) can elevate prolactin levels and confound the results. Thus, an elevated prolactin level can be helpful in identifying a physiologic episode (epileptic seizure or syncope); however, a nonelevated prolactin level does not imply PNES.",
"     </li>",
"     <li>",
"      Other serum markers have been used to help distinguish PNES from epileptic seizures and other physiologic events. These include: creatine phosphokinase (CPK), cortisol, white blood cell count, lactate dehydrogenase, pCO2, ammonia, and neuron specific enolase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/138-141\">",
"       138-141",
"      </a>",
"      ]. CPK levels in particular are often elevated after generalized tonic-clonic seizures, but not after partial seizures. The later rise and prolonged elevation, up to 24 hours postictally, makes this test somewhat more useful in the outpatient setting. However, a defined threshold level for abnormality, sensitivity, and specificity remain to be determined for CPK, as for other serum markers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/142,143\">",
"       142,143",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a structural abnormality is seen on brain MRI, it suggests a neuroanatomic substrate for epilepsy, and provides support for a diagnosis of epilepsy. However, many series report abnormal brain MRI in 10 to 38 percent of patients with PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/16,23,33,110,144\">",
"     16,23,33,110,144",
"    </a>",
"    ]. At the same time, many patients with epileptic seizures have normal brain MRI. Abnormalities identified in PNES patients include arachnoid cyst, post-traumatic or gliotic change, hippocampal sclerosis, and venous angioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities on interictal single photon emission computed tomography (SPECT) are also reported in PNES as well as epilepsy cases. However, a change in focal perfusion from in an ictal or postictal SPECT compared to an interictal SPECT can help distinguish epileptic seizures from PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/144-148\">",
"     144-148",
"    </a>",
"    ]. This technique may be particularly useful when movement-related muscle artifact obscures EEG interpretation. However, this test is not widely available, and the sensitivity and specificity are uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neuropsychological testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychological testing typically assesses both cognitive functioning as well as some psychological domains. The common occurrence of cognitive deficits, particularly in attention and memory, in both PNES and epilepsy patients limits the utility of neuropsychological testing for distinguishing between them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/28,80,110,149-151\">",
"     28,80,110,149-151",
"    </a>",
"    ]. Some of these deficits may be related to antiepileptic drugs and other medications. Neuropsychological testing may be suspicious for PNES when a pattern of failure to recognize words presented repeatedly is exhibited in the face of only rarely making false positive errors (termed a \"negative response bias\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/152,153\">",
"     152,153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Personality profile testing such as the Minnesota Multiphasic Personality Inventory (MMPI), a common component of neuropsychological testing, can be helpful in supplementing formal psychiatric evaluations and highlighting comorbid psychiatric disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/154\">",
"     154",
"    </a>",
"    ]. Patients with PNES typically have high scores on somatization, hypochondriasis, and hysteria subscales [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/24,33,118,154-156\">",
"     24,33,118,154-156",
"    </a>",
"    ]. While a helpful adjunct in the evaluation of patients, studies give varying estimates of its ability to correctly categorize PNES versus epilepsy patients ranging from 70 to 90 percent.",
"   </p>",
"   <p>",
"    One group developed a self-administered screening questionnaire that in a validation cohort had an 85 percent sensitivity and an 85 percent specificity for distinguishing PNES from epileptic seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/157\">",
"     157",
"    </a>",
"    ]. This questionnaire was based primarily on items that were culled from other psychosocial scales that question patients about attitudes toward health and lifestyle, self efficacy, and symptoms of anxiety and depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Psychiatric evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;While essential in the evaluation of patients with suspected PNES, the role of psychiatric evaluation is not to establish or refute a PNES diagnosis, but rather to identify comorbid or underlying psychiatric conditions that will hopefully direct treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/23,73,87,116\">",
"     23,73,87,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An experienced clinician in a detailed psychiatric interview will elicit clinical features that may establish a diagnosis of depression, anxiety, somatoform, dissociative, and other disorders. Sufficient rapport may also be established in this setting, which allows for a previously unreported history of sexual abuse or other trauma to be revealed. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Psychosocial history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Findings on neuropsychological testing may supplement the interview in arriving at one or more psychiatric disorders. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Neuropsychological testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PRESENTING THE DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presenting the diagnosis of PNES to patients is a challenge. Most agree that this should not take place until the clinician feels very definite about the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/158,159\">",
"     158,159",
"    </a>",
"    ]. Care providers who take on this role should be well-trained in delivering this information. Clinicians may prefer to reveal the diagnosis in a separate outpatient meeting rather than in the video-EEG monitoring unit.",
"   </p>",
"   <p>",
"    This conversation is crucially important for the patient's prognosis. Because most serious morbidity associated with PNES is from inappropriate aggressive treatment of presumed epileptic seizures, it is important for the patient and family to accept the diagnosis of PNES in order to avoid emergency room visits, as well as to obtain appropriate psychiatric treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/15,159\">",
"     15,159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A useful method for communicating the diagnosis of PNES to patients emphasizes the presentation in a nonjudgmental fashion that strives to maintain patient dignity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/116,160\">",
"     116,160",
"    </a>",
"    ]. Techniques and talking points that we and others have found useful in this conversation include some of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/84,160\">",
"     84,160",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We state that we do not consider the episodes to be caused by epileptic discharges, but rather represent \"the mind playing tricks on the body.\"",
"     </li>",
"     <li>",
"      We emphasize that this problem is as serious as one caused by epilepsy and deserves the attention and treatment that is accorded any illness.",
"     </li>",
"     <li>",
"      We discuss how stress afflicts each of us to variable degrees and in different ways. We note that \"the body needs to blow off steam\" in some fashion; some people release this stress with the development of headaches, others with tremors, and some with nonepileptic seizures.",
"     </li>",
"     <li>",
"      We emphasize that the episodes are experienced as real and disabling, and that although they relate to emotional or psychological causes, we do not dismiss the problem, and we do not consider the patient to be \"crazy.\"",
"     </li>",
"     <li>",
"      We state that their disorder warrants different treatments than those administered for epilepsy.",
"     </li>",
"     <li>",
"      We tell our patients that we expect that they may react in many ways to this diagnosis. Many patients become angry in response to receiving the diagnosis. Some may acknowledge these feelings, while others may not. An angry reaction may forebode a poor prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/17,111\">",
"       17,111",
"      </a>",
"      ]. In my experience, it is useful to anticipate these feelings at the time of revealing the diagnosis.",
"     </li>",
"     <li>",
"      We and others have also found that patients may exhibit exacerbations of their episodes after the diagnosis is revealed and we often warn the patients not to be surprised if this were to occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study used a semi-structured interview and a printed leaflet that emphasized many of these points, among others, in communicating a new diagnosis of PNES to 50 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/161\">",
"     161",
"    </a>",
"    ]. The investigators felt that these patients responded more positively and had better outcomes than those in whom this approach was not utilized, but there was no control group in this study for direct comparison.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     NEUROLOGIC FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frequent error on the part of neurologists is the immediate discharge of patients with PNES, with the rationale that the diagnosis is psychiatric and not neurologic. In fact, some experts advise instead that PNES patients should not be discharged from the neurologist's care until patients and families accept the fact that they do not have epilepsy, have transitioned to psychiatric care, and have agreed on the time to discontinue neurologic care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/159,162\">",
"     159,162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Premature discharge can exacerbate episodes and increase resistance to accepting the diagnosis. Patients often report a poor understanding of the diagnosis and may complain in a follow-up that they did not receive a clarification of diagnosis even if a thorough discussion was rendered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/17,163\">",
"     17,163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ideally, a close dialogue should also be developed and maintained between neurologic, psychiatric, and primary care providers, who often disagree about the diagnosis and the accuracy of video-EEG monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/17,85,116,159,164\">",
"     17,85,116,159,164",
"    </a>",
"    ]. This communication may limit mixed and conflicting messages from different doctors that can contribute to the overall poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cautious discontinuation of antiepileptic drug (AED) therapy should be coordinated where possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/116\">",
"     116",
"    </a>",
"    ]. It is not infrequent for episodes to increase during this time period. In some cases, epileptic seizures as well as PNES emerge during this interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/165\">",
"     165",
"    </a>",
"    ]. Repeat video-EEG monitoring may be needed if there is doubt that these episodes are different in nature than those documented to be PNES. Some AEDs have mood stabilizing properties and their discontinuation may exacerbate an underlying affective or panic disorder. One small randomized study suggested that early withdrawal of AEDs may be associated with some benefits, including decreased use of rescue AED treatment and higher employment rates at 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/166\">",
"     166",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While some patients relinquish episodes soon after the diagnosis is revealed, most will continue to have episodes and will require long-term psychiatric interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/22,28,83,158,167,168\">",
"     22,28,83,158,167,168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment recommendations in PNES are mostly based upon anecdotal experience or small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/169-171\">",
"     169-171",
"    </a>",
"    ]. There are few published, large, randomized, double-blind treatment trials for PNES, although other such trials are underway. One problem in designing treatments and trials to assess their efficacy relates to the heterogeneous combinations of psychiatric disorders that underlie PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/158\">",
"     158",
"    </a>",
"    ]. Additionally, patients with PNES often do not adhere to treatment recommendations or return for follow-up, and may be particularly disinclined to enroll in treatment trials.",
"   </p>",
"   <p>",
"    Psychiatric interventions are the hallmark of treatment for PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/116\">",
"     116",
"    </a>",
"    ]. These are individualized according to the underlying psychiatric diagnosis. One common psychiatric intervention is traditional psychotherapy. Reports on the success of this intervention are mixed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/167,172\">",
"     167,172",
"    </a>",
"    ]. Group therapy sessions also employ traditional psychodynamic techniques and have had mixed results in open-label studies of PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/171,173,174\">",
"     171,173,174",
"    </a>",
"    ]. The high prevalence of family problems in patients with PNES offer promise that family-related education and interventions may be useful, but these have not been systematically studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive behavioral therapy (CBT) is brief psychosocial intervention that is comprised of a variety of therapeutic approaches. All of the approaches share the basic assumption that therapeutic change can be effected by targeting changes in thoughts (beliefs and attitudes) and behaviors that contribute to emotional distress. An approach based upon a fear avoidance model may be especially successful for patients who have PNES as a dissociative response in stressful circumstances. Small observational case series suggest that CBT may be helpful in reducing episodes and improving psychosocial functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/175,176\">",
"     175,176",
"    </a>",
"    ]. A randomized controlled trial compared CBT to standard medical care in 66 patients with PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/177\">",
"     177",
"    </a>",
"    ]. After four months of treatment, patients on active treatment had a lower median monthly frequency of seizures (2.0 versus 6.75). There was also a trend toward efficacy in more patients achieving a three month seizure remission (OR=3.1; p=0.086). There was no effect of treatment on psychosocial function, health service use, or employment.",
"   </p>",
"   <p>",
"    Psychodynamic interpersonal therapy is an alternative form of psychotherapy. In a case series of 47 patients with PNES, this intervention was associated with seizure remission in 25 percent, and a &gt;50 percent seizure reduction in 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antidepressants and anxiolytics may be prescribed. These may better address psychiatric comorbidities of depression and anxiety rather than an underlying causative psychiatric disorder. These medications have had mixed results in open-label studies of PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/170,171,179\">",
"     170,171,179",
"    </a>",
"    ]. In a pilot study, 38 patients with PNES were randomly assigned to treatment with flexible-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/180\">",
"     180",
"    </a>",
"    ]. Active treatment was associated with a nonsignificant reduction in PNES frequency.",
"   </p>",
"   <p>",
"    Barriers to effective treatment of PNES patients include poor compliance and financial and insurance-related limitations for ongoing treatment. Another challenge is the difficulty finding psychiatric providers who are well-acquainted and comfortable dealing with PNES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Driving",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data regarding driving safety in patients with PNES. While many physicians recommend driving restrictions to their patients with PNES, the little available evidence has not demonstrated that patients with PNES are at increased risk of motor vehicle accidents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/181-184\">",
"     181-184",
"    </a>",
"    ]. In the absence of data supporting that patients with PNES in general are at risk of MVA, we suggest that such decisions be individualized based on the nature of the episodes, the diagnostic certainty, any precipitating factors or situations, and the patient's overall neuropsychiatric condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies that have assessed the prognosis in patients after PNES diagnosis suggest that only a minority (25 to 38 percent) of patients achieve seizure freedom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/4,17,23,33,83,185\">",
"     4,17,23,33,83,185",
"    </a>",
"    ]. Children have a better prognosis than adults, with 70 to 80 percent achieving seizure remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/186\">",
"     186",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While outcome is often reported as a percent of those with seizure remission, this narrow measure does not necessarily reflect the overall clinical outcome with respect to psychiatric and psychosocial status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/4,23,175,187\">",
"     4,23,175,187",
"    </a>",
"    ]. As an example, in one study, 56 percent of patients overall continued to depend on state-supported financial benefits at four years after PNES diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. The percentage was lower, but still substantial, 43 percent, among those in episode remission. Other studies have also found that occupational status, while more likely to improve if PNES cease, often does not, even when episodes do remit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/50,188\">",
"     50,188",
"    </a>",
"    ]. Some studies suggest that psychosocial issues and depression, rather than persistent PNES, are more directly related to disability and reduced quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/175,189\">",
"     175,189",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both attempted and successful suicides have been reported in some series with follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/50,175,190\">",
"     50,175,190",
"    </a>",
"    ]. In one of these cohorts, suicide attempts were equally frequent (11 of 56 patients overall) in those with or without seizure remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/50\">",
"     50",
"    </a>",
"    ]. There is limited evidence to suggest that there may be a modest increase in premature mortality in patients with PNES [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/191\">",
"     191",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients may develop new somatic complaints after their PNES remit. A structured interview of 56 patients, six or more months following PNES diagnosis, revealed moderate to severe pain syndromes, especially headaches, in 77 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/48\">",
"     48",
"    </a>",
"    ]. Twenty-six of 27 patients who stopped experiencing PNES still experienced moderate pain. While the etiologies or other details about these pain symptoms were not studied, it is possible that pain developed de novo or became more serious after the PNES diagnosis. Other studies, however, suggested that development of new somatic complaints was not common, at least within the first six months after PNES diagnosis, and was similarly frequent in those whose PNES persisted as those whose PNES remitted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/83,192\">",
"     83,192",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the risk factors inconsistently associated with a worse prognosis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/5,22,23,48,50,83,84,127,162,172,185,193,194\">",
"     5,22,23,48,50,83,84,127,162,172,185,193,194",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Longer duration of symptoms",
"     </li>",
"     <li>",
"      Older age at onset",
"     </li>",
"     <li>",
"      Lower educational level, lower IQ",
"     </li>",
"     <li>",
"      More isolation, more limited family support",
"     </li>",
"     <li>",
"      Dependent lifestyle",
"     </li>",
"     <li>",
"      No formal treatment plan",
"     </li>",
"     <li>",
"      Unrelieved stressors (eg, ongoing abuse, family conflict)",
"     </li>",
"     <li>",
"      Anger, rejection of PNES diagnosis",
"     </li>",
"     <li>",
"      More severe underlying psychiatric disorder, especially severe or generalized somatization or dissociative symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some studies have associated clinical semiology with prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/23,162,194\">",
"     23,162,194",
"    </a>",
"    ]. Patients with more dramatic motor features, self-injury, and prolonged episodes have a lower likelihood of remission than those with more passive or catatonic-like behaviors. However, the reason behind this association is unclear, and this finding is not universal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/28/33226/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychogenic nonepileptic seizures (PNES) are events that clinically mimic epileptic seizures, but are not associated with physiological central nervous system dysfunction and are instead psychogenically determined.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PNES include a variety of clinical manifestations, some of which are suggestive, although not diagnostic, in distinguishing PNES from epileptic seizures (",
"      <a class=\"graphic graphic_table graphicRef77773 \" href=\"mobipreview.htm?5/53/5980\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features of events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PNES is generally established by video-EEG monitoring, in which captured clinical events are examined in conjunction with electroencephalographic activity. Most patients with PNES will have an event within a few days of monitoring. The use of techniques to induce events is somewhat controversial, but can be helpful diagnostically, when patients do not have an event on monitoring. Other tests (interictal EEG, neuroimaging, neuropsychological tests, and laboratory studies) can be helpful in the evaluation of patients, but are generally not diagnostic of PNES. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Frontal lobe seizures can have atypical clinical features and a normal ictal EEG and can be confused with PNES. Features that suggest that the events are frontal lobe seizures include short duration, stereotyped features, and occurrence during physiologic sleep. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PNES, once established, should be presented to patients and their families in a supportive, nonjudgmental fashion. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Presenting the diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We believe that neurologic follow-up should be maintained after PNES diagnosis to monitor the safe withdrawal of antiepileptic drugs, answer patient questions, and communicate with other treating physicians until such time as the patient has been fully transitioned to psychiatric care. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Neurologic follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychiatric interventions are individualized according to the underlying psychiatric diagnosis and are coordinated by the treating psychiatrist. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis for patients with PNES is guarded. Many patients will continue to have seizure-like events. Patients with and without PNES remission may have substantial psychiatric morbidity and functional limitations on follow-up. Further studies are needed to identify effective psychiatric interventions for these patients. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/1\">",
"      Ozkara C, Dreifuss FE. Differential diagnosis in pseudoepileptic seizures. Epilepsia 1993; 34:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/2\">",
"      DeToledo JC, Lowe MR, Puig A. Nonepileptic seizures in pregnancy. Neurology 2000; 55:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/3\">",
"      Szaflarski JP, Ficker DM, Cahill WT, Privitera MD. Four-year incidence of psychogenic nonepileptic seizures in adults in hamilton county, OH. Neurology 2000; 55:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/4\">",
"      Reuber M, Mitchell AJ, Howlett S, Elger CE. Measuring outcome in psychogenic nonepileptic seizures: how relevant is seizure remission? Epilepsia 2005; 46:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/5\">",
"      Reuber M, Elger CE. Psychogenic nonepileptic seizures: review and update. Epilepsy Behav 2003; 4:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/6\">",
"      Smith PE, Saunders J, Dawson A, Kerr MP. Intractable seizures in pregnancy. Lancet 1999; 354:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/7\">",
"      Gunatilake SB, De Silva HJ, Ranasinghe G. Twenty-seven venous cutdowns to treat pseudostatus epilepticus. Seizure 1997; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/8\">",
"      Peters G, Leach JP, Larner AJ. Pseudostatus epilepticus in pregnancy. Int J Gynaecol Obstet 2007; 97:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/9\">",
"      Tuxhorn IE, Fischbach HS. Pseudostatus epilepticus in childhood. Pediatr Neurol 2002; 27:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/10\">",
"      Wilner AN, Bream PR. Status epilepticus and pseudostatus epilepticus. Seizure 1993; 2:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/11\">",
"      Bateman DE. Pseudostatus epilepticus. Lancet 1989; 2:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/12\">",
"      Howell SJ, Owen L, Chadwick DW. Pseudostatus epilepticus. Q J Med 1989; 71:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/13\">",
"      Reuber M, Baker GA, Gill R, et al. Failure to recognize psychogenic nonepileptic seizures may cause death. Neurology 2004; 62:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/14\">",
"      Reuber M, Pukrop R, Mitchell AJ, et al. Clinical significance of recurrent psychogenic nonepileptic seizure status. J Neurol 2003; 250:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/15\">",
"      Martin RC, Gilliam FG, Kilgore M, et al. Improved health care resource utilization following video-EEG-confirmed diagnosis of nonepileptic psychogenic seizures. Seizure 1998; 7:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/16\">",
"      de Timary P, Fouchet P, Sylin M, et al. Non-epileptic seizures: delayed diagnosis in patients presenting with electroencephalographic (EEG) or clinical signs of epileptic seizures. Seizure 2002; 11:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/17\">",
"      Carton S, Thompson PJ, Duncan JS. Non-epileptic seizures: patients' understanding and reaction to the diagnosis and impact on outcome. Seizure 2003; 12:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/18\">",
"      Bhatia MS. Pseudoseizures. Indian Pediatr 2004; 41:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/19\">",
"      Sigurdardottir KR, Olafsson E. Incidence of psychogenic seizures in adults: a population-based study in Iceland. Epilepsia 1998; 39:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/20\">",
"      Benbadis SR, Allen Hauser W. An estimate of the prevalence of psychogenic non-epileptic seizures. Seizure 2000; 9:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/21\">",
"      Gates JR, Ramani V, Whalen S, Loewenson R. Ictal characteristics of pseudoseizures. Arch Neurol 1985; 42:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/22\">",
"      Meierkord H, Will B, Fish D, Shorvon S. The clinical features and prognosis of pseudoseizures diagnosed using video-EEG telemetry. Neurology 1991; 41:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/23\">",
"      Reuber M, Pukrop R, Bauer J, et al. Outcome in psychogenic nonepileptic seizures: 1 to 10-year follow-up in 164 patients. Ann Neurol 2003; 53:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/24\">",
"      Cragar DE, Berry DT, Fakhoury TA, et al. A review of diagnostic techniques in the differential diagnosis of epileptic and nonepileptic seizures. Neuropsychol Rev 2002; 12:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/25\">",
"      Szaflarski JP, Hughes C, Szaflarski M, et al. Quality of life in psychogenic nonepileptic seizures. Epilepsia 2003; 44:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/26\">",
"      Wyllie E, Glazer JP, Benbadis S, et al. Psychiatric features of children and adolescents with pseudoseizures. Arch Pediatr Adolesc Med 1999; 153:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/27\">",
"      McBride AE, Shih TT, Hirsch LJ. Video-EEG monitoring in the elderly: a review of 94 patients. Epilepsia 2002; 43:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/28\">",
"      Krumholz A, Niedermeyer E. Psychogenic seizures: a clinical study with follow-up data. Neurology 1983; 33:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/29\">",
"      Szab&oacute; L, Siegler Z, Zubek L, et al. A detailed semiologic analysis of childhood psychogenic nonepileptic seizures. Epilepsia 2012; 53:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/30\">",
"      Duncan R, Oto M. Predictors of antecedent factors in psychogenic nonepileptic attacks: multivariate analysis. Neurology 2008; 71:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/31\">",
"      Metrick ME, Ritter FJ, Gates JR, et al. Nonepileptic events in childhood. Epilepsia 1991; 32:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/32\">",
"      Holmes GL, Sackellares JC, McKiernan J, et al. Evaluation of childhood pseudoseizures using EEG telemetry and video tape monitoring. J Pediatr 1980; 97:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/33\">",
"      Lancman ME, Brotherton TA, Asconap&eacute; JJ, Penry JK. Psychogenic seizures in adults: a longitudinal analysis. Seizure 1993; 2:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/34\">",
"      Alper K, Devinsky O, Perrine K, et al. Nonepileptic seizures and childhood sexual and physical abuse. Neurology 1993; 43:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/35\">",
"      Scheepers B, Budd S, Curry S, et al. Non-epileptic attack disorder: a clinical audit. Seizure 1994; 3:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/36\">",
"      Couprie W, Wijdicks EF, Rooijmans HG, van Gijn J. Outcome in conversion disorder: a follow up study. J Neurol Neurosurg Psychiatry 1995; 58:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/37\">",
"      Grattan-Smith P, Fairley M, Procopis P. Clinical features of conversion disorder. Arch Dis Child 1988; 63:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/38\">",
"      Avbersek A, Sisodiya S. Does the primary literature provide support for clinical signs used to distinguish psychogenic nonepileptic seizures from epileptic seizures? J Neurol Neurosurg Psychiatry 2010; 81:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/39\">",
"      Syed TU, LaFrance WC Jr, Kahriman ES, et al. Can semiology predict psychogenic nonepileptic seizures? A prospective study. Ann Neurol 2011; 69:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/40\">",
"      Reuber M, Jamnadas-Khoda J, Broadhurst M, et al. Psychogenic nonepileptic seizure manifestations reported by patients and witnesses. Epilepsia 2011; 52:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/41\">",
"      Benbadis SR. A spell in the epilepsy clinic and a history of \"chronic pain\" or \"fibromyalgia\" independently predict a diagnosis of psychogenic seizures. Epilepsy Behav 2005; 6:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/42\">",
"      Luther JS, McNamara JO, Carwile S, et al. Pseudoepileptic seizures: methods and video analysis to aid diagnosis. Ann Neurol 1982; 12:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/43\">",
"      Woollacott IO, Scott C, Fish DR, et al. When do psychogenic nonepileptic seizures occur on a video/EEG telemetry unit? Epilepsy Behav 2010; 17:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/44\">",
"      Kanner AM, Morris HH, L&uuml;ders H, et al. Supplementary motor seizures mimicking pseudoseizures: some clinical differences. Neurology 1990; 40:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/45\">",
"      Benbadis SR, Lancman ME, King LM, Swanson SJ. Preictal pseudosleep: a new finding in psychogenic seizures. Neurology 1996; 47:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/46\">",
"      Duncan R, Oto M, Russell AJ, Conway P. Pseudosleep events in patients with psychogenic non-epileptic seizures: prevalence and associations. J Neurol Neurosurg Psychiatry 2004; 75:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/47\">",
"      Luciano, D, Devinsky, O, Perrine, K, et al. Psychic stress as a seizure precipitant- relationship to seizure type and region of ictal onset [abstract]. Epilepsia 1996; 32:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/48\">",
"      Ettinger AB, Devinsky O, Weisbrot DM, et al. Headaches and other pain symptoms among patients with psychogenic non-epileptic seizures. Seizure 1999; 8:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/49\">",
"      Ettinger, AB, Weisbrot, DM, Devinsky, O. Patient reporting of seizure exacerbation near the time of menses helps distinguish epileptic from nonepileptic seizures. J Epilepsy 1998; 11:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/50\">",
"      Ettinger AB, Devinsky O, Weisbrot DM, et al. A comprehensive profile of clinical, psychiatric, and psychosocial characteristics of patients with psychogenic nonepileptic seizures. Epilepsia 1999; 40:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/51\">",
"      Leis AA, Ross MA, Summers AK. Psychogenic seizures: ictal characteristics and diagnostic pitfalls. Neurology 1992; 42:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/52\">",
"      Gulick TA, Spinks IP, King DW. Pseudoseizures: ictal phenomena. Neurology 1982; 32:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/53\">",
"      Chen DK, Graber KD, Anderson CT, Fisher RS. Sensitivity and specificity of video alone versus electroencephalography alone for the diagnosis of partial seizures. Epilepsy Behav 2008; 13:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/54\">",
"      Azar NJ, Pitiyanuvath N, Vittal NB, et al. A structured questionnaire predicts if convulsions are epileptic or nonepileptic. Epilepsy Behav 2010; 19:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/55\">",
"      Williamson PD, Jobst BC. Frontal lobe epilepsy. Adv Neurol 2000; 84:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/56\">",
"      Wroe SJ, Henley R, John R, Richens A. The clinical value of serum prolactin measurement in the differential diagnosis of complex partial seizures. Epilepsy Res 1989; 3:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/57\">",
"      Wyllie E, L&uuml;ders H, MacMillan JP, Gupta M. Serum prolactin levels after epileptic seizures. Neurology 1984; 34:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/58\">",
"      Geyer JD, Payne TA, Drury I. The value of pelvic thrusting in the diagnosis of seizures and pseudoseizures. Neurology 2000; 54:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/59\">",
"      Saygi S, Katz A, Marks DA, Spencer SS. Frontal lobe partial seizures and psychogenic seizures: comparison of clinical and ictal characteristics. Neurology 1992; 42:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/60\">",
"      Jobst BC, Williamson PD. Frontal lobe seizures. Psychiatr Clin North Am 2005; 28:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/61\">",
"      Seneviratne U, Reutens D, D'Souza W. Stereotypy of psychogenic nonepileptic seizures: insights from video-EEG monitoring. Epilepsia 2010; 51:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/62\">",
"      Oliva M, Pattison C, Carino J, et al. The diagnostic value of oral lacerations and incontinence during convulsive \"seizures\". Epilepsia 2008; 49:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/63\">",
"      DeToledo JC, Ramsay RE. Patterns of involvement of facial muscles during epileptic and nonepileptic events: review of 654 events. Neurology 1996; 47:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/64\">",
"      Bell WL, Park YD, Thompson EA, Radtke RA. Ictal cognitive assessment of partial seizures and pseudoseizures. Arch Neurol 1998; 55:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/65\">",
"      Bergen D, Ristanovic R. Weeping as a common element of pseudoseizures. Arch Neurol 1993; 50:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/66\">",
"      Singh RB, Niaz MA, Ghosh S, et al. Epidemiological study of magnesium status and risk of coronary artery disease in elderly rural and urban populations of north India. Magnes Res 1996; 9:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/67\">",
"      Vossler DG, Haltiner AM, Schepp SK, et al. Ictal stuttering: a sign suggestive of psychogenic nonepileptic seizures. Neurology 2004; 63:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/68\">",
"      James MR, Marshall H, Carew-McColl M. Pulse oximetry during apparent tonic-clonic seizures. Lancet 1991; 337:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/69\">",
"      Elzawahry H, Do CS, Lin K, Benbadis SR. The diagnostic utility of the ictal cry. Epilepsy Behav 2010; 18:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/70\">",
"      Opherk C, Hirsch LJ. Ictal heart rate differentiates epileptic from non-epileptic seizures. Neurology 2002; 58:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/71\">",
"      Azar NJ, Tayah TF, Wang L, et al. Postictal breathing pattern distinguishes epileptic from nonepileptic convulsive seizures. Epilepsia 2008; 49:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/72\">",
"      Syed TU, Arozullah AM, Suciu GP, et al. Do observer and self-reports of ictal eye closure predict psychogenic nonepileptic seizures? Epilepsia 2008; 49:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/73\">",
"      Berkhoff M, Briellmann RS, Radanov BP, et al. Developmental background and outcome in patients with nonepileptic versus epileptic seizures: a controlled study. Epilepsia 1998; 39:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/74\">",
"      Gumnit RJ, Gates JR. Psychogenic seizures. Epilepsia 1986; 27 Suppl 2:S124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/75\">",
"      Hubsch C, Baumann C, Hingray C, et al. Clinical classification of psychogenic non-epileptic seizures based on video-EEG analysis and automatic clustering. J Neurol Neurosurg Psychiatry 2011; 82:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/76\">",
"      Wennberg R. Postictal coughing and noserubbing coexist in temporal lobe epilepsy. Neurology 2001; 56:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/77\">",
"      van Merode T, Twellaar M, Kotsopoulos IA, et al. Psychological characteristics of patients with newly developed psychogenic seizures. J Neurol Neurosurg Psychiatry 2004; 75:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/78\">",
"      Westbrook LE, Devinsky O, Geocadin R. Nonepileptic seizures after head injury. Epilepsia 1998; 39:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/79\">",
"      Galimberti CA, Ratti MT, Murelli R, et al. Patients with psychogenic nonepileptic seizures, alone or epilepsy-associated, share a psychological profile distinct from that of epilepsy patients. J Neurol 2003; 250:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/80\">",
"      Strutt AM, Hill SW, Scott BM, et al. A comprehensive neuropsychological profile of women with psychogenic nonepileptic seizures. Epilepsy Behav 2011; 20:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/81\">",
"      Bowman ES. Etiology and clinical course of pseudoseizures. Relationship to trauma, depression, and dissociation. Psychosomatics 1993; 34:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/82\">",
"      Reuber M, Pukrop R, Bauer J, et al. Multidimensional assessment of personality in patients with psychogenic non-epileptic seizures. J Neurol Neurosurg Psychiatry 2004; 75:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/83\">",
"      Kanner AM, Parra J, Frey M, et al. Psychiatric and neurologic predictors of psychogenic pseudoseizure outcome. Neurology 1999; 53:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/84\">",
"      Bowman ES. Nonepileptic seizures: psychiatric framework, treatment, and outcome. Neurology 1999; 53:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/85\">",
"      Lacey C, Cook M, Salzberg M. The neurologist, psychogenic nonepileptic seizures, and borderline personality disorder. Epilepsy Behav 2007; 11:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/86\">",
"      Harden CL, Jovine L, Burgut FT, et al. A comparison of personality disorder characteristics of patients with nonepileptic psychogenic pseudoseizures with those of patients with epilepsy. Epilepsy Behav 2009; 14:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/87\">",
"      Testa SM, Lesser RP, Krauss GL, Brandt J. Personality Assessment Inventory among patients with psychogenic seizures and those with epilepsy. Epilepsia 2011; 52:e84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/88\">",
"      Rosenberg HJ, Rosenberg SD, Williamson PD, Wolford GL 2nd. A comparative study of trauma and posttraumatic stress disorder prevalence in epilepsy patients and psychogenic nonepileptic seizure patients. Epilepsia 2000; 41:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/89\">",
"      Paras ML, Murad MH, Chen LP, et al. Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis. JAMA 2009; 302:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/90\">",
"      Koby DG, Zirakzadeh A, Staab JP, et al. Questioning the role of abuse in behavioral spells and epilepsy. Epilepsy Behav 2010; 19:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/91\">",
"      Selkirk M, Duncan R, Oto M, Pelosi A. Clinical differences between patients with nonepileptic seizures who report antecedent sexual abuse and those who do not. Epilepsia 2008; 49:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/92\">",
"      Krawetz P, Fleisher W, Pillay N, et al. Family functioning in subjects with pseudoseizures and epilepsy. J Nerv Ment Dis 2001; 189:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/93\">",
"      Moore PM, Baker GA, McDade G, et al. Epilepsy, pseudoseizures and perceived family characteristics: a controlled study. Epilepsy Res 1994; 18:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/94\">",
"      Wood BL, McDaniel S, Burchfiel K, Erba G. Factors distinguishing families of patients with psychogenic seizures from families of patients with epilepsy. Epilepsia 1998; 39:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/95\">",
"      Lawton G, Baker GA, Brown RJ. Comparison of two types of dissociation in epileptic and nonepileptic seizures. Epilepsy Behav 2008; 13:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/96\">",
"      Patel H, Scott E, Dunn D, Garg B. Nonepileptic seizures in children. Epilepsia 2007; 48:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/97\">",
"      Bowman ES, Markand ON. The contribution of life events to pseudoseizure occurrence in adults. Bull Menninger Clin 1999; 63:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/98\">",
"      Benbadis SR, Agrawal V, Tatum WO 4th. How many patients with psychogenic nonepileptic seizures also have epilepsy? Neurology 2001; 57:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/99\">",
"      Parra J, Iriarte J, Kanner AM. Are we overusing the diagnosis of psychogenic non-epileptic events? Seizure 1999; 8:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/100\">",
"      Martin R, Burneo JG, Prasad A, et al. Frequency of epilepsy in patients with psychogenic seizures monitored by video-EEG. Neurology 2003; 61:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/101\">",
"      Lesser RP, Lueders H, Dinner DS. Evidence for epilepsy is rare in patients with psychogenic seizures. Neurology 1983; 33:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/102\">",
"      Reuber M, Fern&aacute;ndez G, Bauer J, et al. Interictal EEG abnormalities in patients with psychogenic nonepileptic seizures. Epilepsia 2002; 43:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/103\">",
"      Devinsky O, Sanchez-Villase&ntilde;or F, Vazquez B, et al. Clinical profile of patients with epileptic and nonepileptic seizures. Neurology 1996; 46:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/104\">",
"      Henry TR, Drury I. Ictal behaviors during nonepileptic seizures differ in patients with temporal lobe interictal epileptiform EEG activity and patients without interictal epileptiform EEG abnormalities. Epilepsia 1998; 39:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/105\">",
"      Ney GC, Barr WB, Napolitano C, et al. New-onset psychogenic seizures after surgery for epilepsy. Arch Neurol 1998; 55:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/106\">",
"      Glosser G, Roberts D, Glosser DS. Nonepileptic seizures after resective epilepsy surgery. Epilepsia 1999; 40:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/107\">",
"      Parra J, Iriarte J, Kanner AM, Bergen DC. De novo psychogenic nonepileptic seizures after epilepsy surgery. Epilepsia 1998; 39:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/108\">",
"      Bautista RE, Gonzales-Salazar W, Ochoa JG. Expanding the theory of symptom modeling in patents with psychogenic nonepileptic seizures. Epilepsy Behav 2008; 13:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/109\">",
"      Barry E, Krumholz A, Bergey GK, et al. Nonepileptic posttraumatic seizures. Epilepsia 1998; 39:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/110\">",
"      Reuber M, Fern&aacute;ndez G, Helmstaedter C, et al. Evidence of brain abnormality in patients with psychogenic nonepileptic seizures. Epilepsy Behav 2002; 3:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/111\">",
"      M&ouml;kleby K, Blomhoff S, Malt UF, et al. Psychiatric comorbidity and hostility in patients with psychogenic nonepileptic seizures compared with somatoform disorders and healthy controls. Epilepsia 2002; 43:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/112\">",
"      DeToledo JC, Lowe MR, Haddad H. Behaviors mimicking seizures in institutionalized individuals with multiple disabilities and epilepsy: a video-EEG study. Epilepsy Behav 2002; 3:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/113\">",
"      Paolicchi JM. The spectrum of nonepileptic events in children. Epilepsia 2002; 43 Suppl 3:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/114\">",
"      Stone J, Smyth R, Carson A, et al. La belle indiff&eacute;rence in conversion symptoms and hysteria: systematic review. Br J Psychiatry 2006; 188:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/115\">",
"      Seneviratne U, Rajendran D, Brusco M, Phan TG. How good are we at diagnosing seizures based on semiology? Epilepsia 2012; 53:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/116\">",
"      Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011; 52:2133.",
"     </a>",
"    </li>",
"    <li>",
"     Ramani, V. Intensive monitoring of psychogenic seizures, aggression, and dyscontrol syndromes. In: Advances in Neurology, Gumnit RJ (Ed), Raven Press, New York 1986. p.203.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/118\">",
"      Storzbach D, Binder LM, Salinsky MC, et al. Improved prediction of nonepileptic seizures with combined MMPI and EEG measures. Epilepsia 2000; 41:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/119\">",
"      Parra J, Kanner AM, Iriarte J, Gil-Nagel A. When should induction protocols be used in the diagnostic evaluation of patients with paroxysmal events? Epilepsia 1998; 39:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/120\">",
"      Perrin MW, Sahoo SK, Goodkin HP. Latency to first psychogenic nonepileptic seizure upon admission to inpatient EEG monitoring: evidence for semiological differences. Epilepsy Behav 2010; 19:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/121\">",
"      Devinsky O, Kelley K, Porter RJ, Theodore WH. Clinical and electroencephalographic features of simple partial seizures. Neurology 1988; 38:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/122\">",
"      Benbadis SR, LaFrance WC Jr, Papandonatos GD, et al. Interrater reliability of EEG-video monitoring. Neurology 2009; 73:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/123\">",
"      Benbadis SR, Johnson K, Anthony K, et al. Induction of psychogenic nonepileptic seizures without placebo. Neurology 2000; 55:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/124\">",
"      McGonigal A, Oto M, Russell AJ, et al. Outpatient video EEG recording in the diagnosis of non-epileptic seizures: a randomised controlled trial of simple suggestion techniques. J Neurol Neurosurg Psychiatry 2002; 72:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/125\">",
"      Slater JD, Brown MC, Jacobs W, Ramsay RE. Induction of pseudoseizures with intravenous saline placebo. Epilepsia 1995; 36:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/126\">",
"      Chen DK, Izadyar S, Collins RL, et al. Induction of psychogenic nonepileptic events: success rate influenced by prior induction exposure, ictal semiology, and psychological profiles. Epilepsia 2011; 52:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/127\">",
"      Lesser RP. Psychogenic seizures. Neurology 1996; 46:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/128\">",
"      Walczak TS, Williams DT, Berten W. Utility and reliability of placebo infusion in the evaluation of patients with seizures. Neurology 1994; 44:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/129\">",
"      Lancman ME, Asconap&eacute; JJ, Craven WJ, et al. Predictive value of induction of psychogenic seizures by suggestion. Ann Neurol 1994; 35:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/130\">",
"      Bazil CW, Kothari M, Luciano D, et al. Provocation of nonepileptic seizures by suggestion in a general seizure population. Epilepsia 1994; 35:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/131\">",
"      Leeman BA. Provocative techniques should not be used for the diagnosis of psychogenic nonepileptic seizures. Epilepsy Behav 2009; 15:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/132\">",
"      Gates JR. Provocative testing should not be used for nonepileptic seizures. Arch Neurol 2001; 58:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/133\">",
"      Benbadis SR. Provocative techniques should be used for the diagnosis of psychogenic nonepileptic seizures. Epilepsy Behav 2009; 15:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/134\">",
"      Devinsky O, Fisher R. Ethical use of placebos and provocative testing in diagnosing nonepileptic seizures. Neurology 1996; 47:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/135\">",
"      Chen DK, So YT, Fisher RS, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/136\">",
"      Sperling MR, Pritchard PB 3rd, Engel J Jr, et al. Prolactin in partial epilepsy: an indicator of limbic seizures. Ann Neurol 1986; 20:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/137\">",
"      Oribe E, Amini R, Nissenbaum E, Boal B. Serum prolactin concentrations are elevated after syncope. Neurology 1996; 47:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/138\">",
"      Willert C, Spitzer C, Kusserow S, Runge U. Serum neuron-specific enolase, prolactin, and creatine kinase after epileptic and psychogenic non-epileptic seizures. Acta Neurol Scand 2004; 109:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/139\">",
"      Pritchard PB 3rd, Wannamaker BB, Sagel J, Daniel CM. Serum prolactin and cortisol levels in evaluation of pseudoepileptic seizures. Ann Neurol 1985; 18:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/140\">",
"      Shah AK, Shein N, Fuerst D, et al. Peripheral WBC count and serum prolactin level in various seizure types and nonepileptic events. Epilepsia 2001; 42:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/141\">",
"      Hung TY, Chen CC, Wang TL, et al. Transient hyperammonemia in seizures: a prospective study. Epilepsia 2011; 52:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/142\">",
"      Wyllie E, Lueders H, Pippenger C, VanLente F. Postictal serum creatine kinase in the diagnosis of seizure disorders. Arch Neurol 1985; 42:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/143\">",
"      Petramfar P, Yaghoobi E, Nemati R, Asadi-Pooya AA. Serum creatine phosphokinase is helpful in distinguishing generalized tonic-clonic seizures from psychogenic nonepileptic seizures and vasovagal syncope. Epilepsy Behav 2009; 15:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/144\">",
"      Ettinger, AB, Jandorf, L, Cabahug, CJ, et al. Post-ictal SPECT in epileptic vs. non-epileptic seizures. J Epilepsy 1998; 11:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/145\">",
"      Spanaki MV, Spencer SS, Corsi M, et al. The role of quantitative ictal SPECT analysis in the evaluation of nonepileptic seizures. J Neuroimaging 1999; 9:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/146\">",
"      Biraben A, Taussig D, Bernard AM, et al. Video-EEG and ictal SPECT in three patients with both epileptic and non-epileptic seizures. Epileptic Disord 1999; 1:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/147\">",
"      Varma AR, Moriarty J, Costa DC, et al. HMPAO SPECT in non-epileptic seizures: preliminary results. Acta Neurol Scand 1996; 94:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/148\">",
"      Neiman ES, Noe KH, Drazkowski JF, et al. Utility of subtraction ictal SPECT when video-EEG fails to distinguish atypical psychogenic and epileptic seizures. Epilepsy Behav 2009; 15:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/149\">",
"      Almgren, PE, Nordgren, L, Skantze, H. A retrospective study of operationally defined hysterics. Br J Psychiatry 1978; 132:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/150\">",
"      Bendefeldt F, Miller LL, Ludwig AM. Cognitive performance in conversion hysteria. Arch Gen Psychiatry 1976; 33:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/151\">",
"      van der Kruijs SJ, Bodde NM, Vaessen MJ, et al. Functional connectivity of dissociation in patients with psychogenic non-epileptic seizures. J Neurol Neurosurg Psychiatry 2012; 83:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/152\">",
"      Bortz JJ, Prigatano GP, Blum D, Fisher RS. Differential response characteristics in nonepileptic and epileptic seizure patients on a test of verbal learning and memory. Neurology 1995; 45:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/153\">",
"      McNally KA, Schefft BK, Szaflarski JP, et al. Application of signal detection theory to verbal memory testing to distinguish patients with psychogenic nonepileptic seizures from patients with epileptic seizures. Epilepsy Behav 2009; 14:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/154\">",
"      Dikmen S, Hermann BP, Wilensky AJ, Rainwater G. Validity of the Minnesota Multiphasic Personality Inventory (MMPI) to psychopathology in patients with epilepsy. J Nerv Ment Dis 1983; 171:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/155\">",
"      Derry PA, McLachlan RS. The MMPI-2 as an adjunct to the diagnosis of pseudoseizures. Seizure 1996; 5:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/156\">",
"      Schramke CJ, Valeri A, Valeriano JP, Kelly KM. Using the Minnesota Multiphasic Inventory 2, EEGs, and clinical data to predict nonepileptic events. Epilepsy Behav 2007; 11:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/157\">",
"      Syed TU, Arozullah AM, Loparo KL, et al. A self-administered screening instrument for psychogenic nonepileptic seizures. Neurology 2009; 72:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/158\">",
"      Lesser RP. Treatment and Outcome of Psychogenic Nonepileptic Seizures. Epilepsy Curr 2003; 3:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/159\">",
"      Kanner AM. More controversies on the treatment of psychogenic pseudoseizures: an addendum. Epilepsy Behav 2003; 4:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/160\">",
"      Shen W, Bowman ES, Markand ON. Presenting the diagnosis of pseudoseizure. Neurology 1990; 40:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/161\">",
"      Hall-Patch L, Brown R, House A, et al. Acceptability and effectiveness of a strategy for the communication of the diagnosis of psychogenic nonepileptic seizures. Epilepsia 2010; 51:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/162\">",
"      Selwa LM, Geyer J, Nikakhtar N, et al. Nonepileptic seizure outcome varies by type of spell and duration of illness. Epilepsia 2000; 41:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/163\">",
"      Thompson R, Isaac CL, Rowse G, et al. What is it like to receive a diagnosis of nonepileptic seizures? Epilepsy Behav 2009; 14:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/164\">",
"      Harden CL, Burgut FT, Kanner AM. The diagnostic significance of video-EEG monitoring findings on pseudoseizure patients differs between neurologists and psychiatrists. Epilepsia 2003; 44:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/165\">",
"      Oto M, Espie C, Pelosi A, et al. The safety of antiepileptic drug withdrawal in patients with non-epileptic seizures. J Neurol Neurosurg Psychiatry 2005; 76:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/166\">",
"      Oto M, Espie CA, Duncan R. An exploratory randomized controlled trial of immediate versus delayed withdrawal of antiepileptic drugs in patients with psychogenic nonepileptic attacks (PNEAs). Epilepsia 2010; 51:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/167\">",
"      Aboukasm A, Mahr G, Gahry BR, et al. Retrospective analysis of the effects of psychotherapeutic interventions on outcomes of psychogenic nonepileptic seizures. Epilepsia 1998; 39:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/168\">",
"      Farias ST, Thieman C, Alsaadi TM. Psychogenic nonepileptic seizures: acute change in event frequency after presentation of the diagnosis. Epilepsy Behav 2003; 4:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/169\">",
"      Silver FW. Management of conversion disorder. Am J Phys Med Rehabil 1996; 75:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/170\">",
"      LaFrance WC Jr, Devinsky O. The treatment of nonepileptic seizures: historical perspectives and future directions. Epilepsia 2004; 45 Suppl 2:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/171\">",
"      LaFrance WC Jr, Barry JJ. Update on treatments of psychological nonepileptic seizures. Epilepsy Behav 2005; 7:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/172\">",
"      Ettinger AB, Dhoon A, Weisbrot DM, Devinsky O. Predictive factors for outcome of nonepileptic seizures after diagnosis. J Neuropsychiatry Clin Neurosci 1999; 11:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/173\">",
"      Zaroff CM, Myers L, Barr WB, et al. Group psychoeducation as treatment for psychological nonepileptic seizures. Epilepsy Behav 2004; 5:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/174\">",
"      Barry JJ, Wittenberg D, Bullock KD, et al. Group therapy for patients with psychogenic nonepileptic seizures: a pilot study. Epilepsy Behav 2008; 13:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/175\">",
"      Goldstein LH, Deale AC, Mitchell-O'Malley SJ, et al. An evaluation of cognitive behavioral therapy as a treatment for dissociative seizures: a pilot study. Cogn Behav Neurol 2004; 17:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/176\">",
"      LaFrance WC Jr, Miller IW, Ryan CE, et al. Cognitive behavioral therapy for psychogenic nonepileptic seizures. Epilepsy Behav 2009; 14:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/177\">",
"      Goldstein LH, Chalder T, Chigwedere C, et al. Cognitive-behavioral therapy for psychogenic nonepileptic seizures: a pilot RCT. Neurology 2010; 74:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/178\">",
"      Mayor R, Howlett S, Gr&uuml;newald R, Reuber M. Long-term outcome of brief augmented psychodynamic interpersonal therapy for psychogenic nonepileptic seizures: seizure control and health care utilization. Epilepsia 2010; 51:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/179\">",
"      Pintor L, Baill&eacute;s E, Matrai S, et al. Efficiency of venlafaxine in patients with psychogenic nonepileptic seizures and anxiety and/or depressive disorders. J Neuropsychiatry Clin Neurosci 2010; 22:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/180\">",
"      LaFrance WC Jr, Keitner GI, Papandonatos GD, et al. Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures. Neurology 2010; 75:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/181\">",
"      Benbadis SR, Blustein JN, Sunstad L. Should patients with psychogenic nonepileptic seizures be allowed to drive? Epilepsia 2000; 41:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/182\">",
"      Shneker BF, Elliott JO. Primary care and emergency physician attitudes and beliefs related to patients with psychogenic nonepileptic spells. Epilepsy Behav 2008; 13:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/183\">",
"      Iriarte J, Parra J, Urrestarazu E, Kuyk J. Controversies in the diagnosis and management of psychogenic pseudoseizures. Epilepsy Behav 2003; 4:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/184\">",
"      Specht U, Thorbecke R. Should patients with psychogenic nonepileptic seizures be allowed to drive? Recommendations of German experts. Epilepsy Behav 2009; 16:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/185\">",
"      McKenzie P, Oto M, Russell A, et al. Early outcomes and predictors in 260 patients with psychogenic nonepileptic attacks. Neurology 2010; 74:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/186\">",
"      Wyllie E, Friedman D, L&uuml;ders H, et al. Outcome of psychogenic seizures in children and adolescents compared with adults. Neurology 1991; 41:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/187\">",
"      Lawton G, Mayor RJ, Howlett S, Reuber M. Psychogenic nonepileptic seizures and health-related quality of life: the relationship with psychological distress and other physical symptoms. Epilepsy Behav 2009; 14:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/188\">",
"      Walczak TS, Papacostas S, Williams DT, et al. Outcome after diagnosis of psychogenic nonepileptic seizures. Epilepsia 1995; 36:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/189\">",
"      LaFrance WC Jr, Syc S. Depression and symptoms affect quality of life in psychogenic nonepileptic seizures. Neurology 2009; 73:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/190\">",
"      Savard G, Andermann F, Teitelbaum J, Lehmann H. Epileptic Munchausen's syndrome: a form of pseudoseizures distinct from hysteria and malingering. Neurology 1988; 38:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/191\">",
"      Duncan R, Oto M, Wainman-Lefley J. Mortality in a cohort of patients with psychogenic non-epileptic seizures. J Neurol Neurosurg Psychiatry 2012; 83:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/192\">",
"      McKenzie PS, Oto M, Graham CD, Duncan R. Do patients whose psychogenic non-epileptic seizures resolve, 'replace' them with other medically unexplained symptoms? Medically unexplained symptoms arising after a diagnosis of psychogenic non-epileptic seizures. J Neurol Neurosurg Psychiatry 2011; 82:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/193\">",
"      Lempert T, Schmidt D. Natural history and outcome of psychogenic seizures: a clinical study in 50 patients. J Neurol 1990; 237:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/28/33226/abstract/194\">",
"      Arain AM, Hamadani AM, Islam S, Abou-Khalil BW. Predictors of early seizure remission after diagnosis of psychogenic nonepileptic seizures. Epilepsy Behav 2007; 11:409.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2227 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-512E5AB897-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33226=[""].join("\n");
var outline_f32_28_33226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES OF EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Precipitants and setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ictal features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Postictal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Response to treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ASSOCIATED FEATURES AND CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Psychosocial history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Concurrent or past epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Seizure model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Comorbid neurologic and medical disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Examination findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Routine EEG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Video-EEG monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Spell induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other monitoring techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Serum testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neuropsychological testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Psychiatric evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PRESENTING THE DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      NEUROLOGIC FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Driving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2227\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2227|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/53/5980\" title=\"table 1\">",
"      Clinical features of psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/38/32364\" title=\"table 2\">",
"      Differential diagnosis of seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29175?source=related_link\">",
"      Nonepileptic paroxysmal disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=related_link\">",
"      Treatment of seizures and epilepsy in the elderly patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=related_link\">",
"      Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_28_33227="Vulvar cancer survival";
var content_f32_28_33227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival by FIGO stage for patients with vulvar cancer 1999 to 2001 FIGO statistics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        FIGO stage",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Overall survival (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        One year",
"       </td>",
"       <td class=\"subtitle2\">",
"        Two years",
"       </td>",
"       <td class=\"subtitle2\">",
"        Five years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        286",
"       </td>",
"       <td>",
"        96.4",
"       </td>",
"       <td>",
"        90.4",
"       </td>",
"       <td>",
"        78.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        266",
"       </td>",
"       <td>",
"        87.6",
"       </td>",
"       <td>",
"        73.2",
"       </td>",
"       <td>",
"        58.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        74.7",
"       </td>",
"       <td>",
"        53.8",
"       </td>",
"       <td>",
"        43.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        35.3",
"       </td>",
"       <td>",
"        16.9",
"       </td>",
"       <td>",
"        13.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FIGO: International Federation of Gynecology and Obstetrics.",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. From: Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. Int J Gynaecol Obstet 2006; 95:S7. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33227=[""].join("\n");
var outline_f32_28_33227=null;
var title_f32_28_33228="Spine injury classification";
var content_f32_28_33228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of spinal injuries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Mechanisms of spinal injury",
"      </td>",
"      <td class=\"subtitle1\">",
"       Stability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Flexion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anterior wedge fracture",
"      </td>",
"      <td>",
"       Stable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Flexion teardrop fracture",
"      </td>",
"      <td>",
"       Extremely unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Clay shoveler's fracture",
"      </td>",
"      <td>",
"       Stable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Subluxation",
"      </td>",
"      <td>",
"       Potentially unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bilateral facet dislocation",
"      </td>",
"      <td>",
"       Always unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Atlanto-occipital dislocation",
"      </td>",
"      <td>",
"       Unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anterior atlantoaxial dislocation with or without fracture",
"      </td>",
"      <td>",
"       Unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Odontoid fracture with lateral displacement",
"      </td>",
"      <td>",
"       Unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fracture of transverse process",
"      </td>",
"      <td>",
"       Stable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Flexion-rotation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Unilateral facet dislocation",
"      </td>",
"      <td>",
"       Stable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rotary atlantoaxial dislocation",
"      </td>",
"      <td>",
"       Unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Extension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Posterior neural arch fracture (C1)",
"      </td>",
"      <td>",
"       Unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hangman's fracture (C2)",
"      </td>",
"      <td>",
"       Unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Extension teardrop fracture",
"      </td>",
"      <td>",
"       Usually stable in flexion; unstable in extension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Posterior atlantoaxial dislocation with or without fracture",
"      </td>",
"      <td>",
"       Unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Vertical compression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Burst fracture of vertebral body",
"      </td>",
"      <td>",
"       Stable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Jefferson fracture (C1)",
"      </td>",
"      <td>",
"       Extremely unstable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Isolated fractures of articular pillar and vertebral body",
"      </td>",
"      <td>",
"       Stable",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marx, JA, Hockberber, RS, Walls, RM. Rosen's emergency medicine: concepts and clinical practice, 6th ed, Mosby, Inc., St. Louis 2006. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33228=[""].join("\n");
var outline_f32_28_33228=null;
var title_f32_28_33229="Incidence of myocardial infarction in men and women";
var content_f32_28_33229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Incidence of myocardial infarction in men and women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 230px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence of myocardial infarction by age and sex in a 26-year follow-up in the Framingham study. The incidence increases with age in both sexes, but occurs later (primarily after menopause) in women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lerner DJ, Kannel WB. Am Heart J 1986; 111:383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33229=[""].join("\n");
var outline_f32_28_33229=null;
var title_f32_28_33230="Insertion Mirena IUD2";
var content_f32_28_33230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insertion Mirena IUD2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After the device is in place, the knobs at the end of the arms cover the open end of the inserter and the threads can be fixed in the cleft of the handle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Berlex. Copyright &copy; Berlex.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33230=[""].join("\n");
var outline_f32_28_33230=null;
var title_f32_28_33231="Eruption hematoma";
var content_f32_28_33231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eruption hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An eruption hematoma over an erupting maxillary permanent central incisor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, MD, Ludwig W, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_28_33231=[""].join("\n");
var outline_f32_28_33231=null;
